EP4355751A1 - Composés hétéroaryle fusionnés utiles en tant qu'agents anticancéreux - Google Patents
Composés hétéroaryle fusionnés utiles en tant qu'agents anticancéreuxInfo
- Publication number
- EP4355751A1 EP4355751A1 EP22740705.3A EP22740705A EP4355751A1 EP 4355751 A1 EP4355751 A1 EP 4355751A1 EP 22740705 A EP22740705 A EP 22740705A EP 4355751 A1 EP4355751 A1 EP 4355751A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- alkyl
- ioaryl
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 218
- 239000002246 antineoplastic agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 274
- 150000003839 salts Chemical class 0.000 claims abstract description 220
- 238000000034 method Methods 0.000 claims abstract description 33
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 569
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 558
- 229910052757 nitrogen Inorganic materials 0.000 claims description 376
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 295
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 260
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 234
- 239000001257 hydrogen Substances 0.000 claims description 216
- 229910052739 hydrogen Inorganic materials 0.000 claims description 216
- 239000012453 solvate Substances 0.000 claims description 197
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 184
- 229910052736 halogen Inorganic materials 0.000 claims description 170
- 150000002367 halogens Chemical group 0.000 claims description 170
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 138
- -1 Ci-6alkyl Chemical group 0.000 claims description 121
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 109
- 125000002950 monocyclic group Chemical group 0.000 claims description 96
- 102000016914 ras Proteins Human genes 0.000 claims description 57
- 108010014186 ras Proteins Proteins 0.000 claims description 56
- 229910052799 carbon Inorganic materials 0.000 claims description 54
- 125000004429 atom Chemical group 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 235000001014 amino acid Nutrition 0.000 claims description 37
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 37
- 235000018102 proteins Nutrition 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 29
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 28
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 25
- 125000003566 oxetanyl group Chemical group 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229910020008 S(O) Inorganic materials 0.000 claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 102100030708 GTPase KRas Human genes 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 102000049555 human KRAS Human genes 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 230000015556 catabolic process Effects 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 10
- 125000005647 linker group Chemical group 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 6
- 102000005446 Anaphase-Promoting Complex-Cyclosome Human genes 0.000 claims description 6
- 108010031677 Anaphase-Promoting Complex-Cyclosome Proteins 0.000 claims description 6
- 102100040341 E3 ubiquitin-protein ligase UBR5 Human genes 0.000 claims description 6
- 101000671838 Homo sapiens E3 ubiquitin-protein ligase UBR5 Proteins 0.000 claims description 6
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 102100032783 Protein cereblon Human genes 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 6
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 5
- 125000004419 alkynylene group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 125000005549 heteroarylene group Chemical group 0.000 claims description 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- IXZOHGPZAQLIBH-NRFANRHFSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-NRFANRHFSA-N 0.000 claims description 3
- DOEVCIHTTTYVCC-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-5-yl]methyl]urea Chemical compound C1=C(Cl)C(C)=CC=C1NC(=O)NCC1=CC=C(C(=O)N(C2)C3C(NC(=O)CC3)=O)C2=C1 DOEVCIHTTTYVCC-UHFFFAOYSA-N 0.000 claims description 3
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims description 3
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 claims description 3
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 3
- 108091007065 BIRCs Proteins 0.000 claims description 3
- 101100160815 Bacillus subtilis (strain 168) yxbF gene Proteins 0.000 claims description 3
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims description 3
- 101710177962 Baculoviral IAP repeat-containing protein 3 Proteins 0.000 claims description 3
- 102100027515 Baculoviral IAP repeat-containing protein 6 Human genes 0.000 claims description 3
- 108700020472 CDC20 Proteins 0.000 claims description 3
- 101150023302 Cdc20 gene Proteins 0.000 claims description 3
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 claims description 3
- 102100025525 Cullin-5 Human genes 0.000 claims description 3
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims description 3
- 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 claims description 3
- 102100039768 DDB1- and CUL4-associated factor 15 Human genes 0.000 claims description 3
- 102100029586 DDB1- and CUL4-associated factor 16 Human genes 0.000 claims description 3
- 102100032917 E3 SUMO-protein ligase CBX4 Human genes 0.000 claims description 3
- 102100035989 E3 SUMO-protein ligase PIAS1 Human genes 0.000 claims description 3
- 102100036254 E3 SUMO-protein ligase PIAS2 Human genes 0.000 claims description 3
- 102100030837 E3 SUMO-protein ligase PIAS3 Human genes 0.000 claims description 3
- 102100030987 E3 SUMO-protein ligase PIAS4 Human genes 0.000 claims description 3
- 102100038912 E3 SUMO-protein ligase RanBP2 Human genes 0.000 claims description 3
- 102100037334 E3 ubiquitin-protein ligase CHIP Human genes 0.000 claims description 3
- 102100030428 E3 ubiquitin-protein ligase E3D Human genes 0.000 claims description 3
- 102100027325 E3 ubiquitin-protein ligase HACE1 Human genes 0.000 claims description 3
- 102100034677 E3 ubiquitin-protein ligase HECTD1 Human genes 0.000 claims description 3
- 102100034678 E3 ubiquitin-protein ligase HECTD3 Human genes 0.000 claims description 3
- 102100034674 E3 ubiquitin-protein ligase HECW1 Human genes 0.000 claims description 3
- 102100034675 E3 ubiquitin-protein ligase HECW2 Human genes 0.000 claims description 3
- 102100034745 E3 ubiquitin-protein ligase HERC2 Human genes 0.000 claims description 3
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 claims description 3
- 102100030370 E3 ubiquitin-protein ligase Hakai Human genes 0.000 claims description 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 3
- 102100031918 E3 ubiquitin-protein ligase NEDD4 Human genes 0.000 claims description 3
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 claims description 3
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 claims description 3
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 claims description 3
- 102100028090 E3 ubiquitin-protein ligase RNF114 Human genes 0.000 claims description 3
- 102100021820 E3 ubiquitin-protein ligase RNF4 Human genes 0.000 claims description 3
- 102100038662 E3 ubiquitin-protein ligase SMURF2 Human genes 0.000 claims description 3
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 claims description 3
- 102100029505 E3 ubiquitin-protein ligase TRIM33 Human genes 0.000 claims description 3
- 102100037460 E3 ubiquitin-protein ligase Topors Human genes 0.000 claims description 3
- 102100037240 E3 ubiquitin-protein ligase UBR2 Human genes 0.000 claims description 3
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 3
- 102100033594 E3 ubiquitin-protein ligase makorin-1 Human genes 0.000 claims description 3
- 102100038576 F-box/WD repeat-containing protein 1A Human genes 0.000 claims description 3
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims description 3
- 102100028650 Glucose-induced degradation protein 4 homolog Human genes 0.000 claims description 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 3
- 101000936081 Homo sapiens Baculoviral IAP repeat-containing protein 6 Proteins 0.000 claims description 3
- 101000856414 Homo sapiens Cullin-5 Proteins 0.000 claims description 3
- 101000885463 Homo sapiens DDB1- and CUL4-associated factor 15 Proteins 0.000 claims description 3
- 101000917435 Homo sapiens DDB1- and CUL4-associated factor 16 Proteins 0.000 claims description 3
- 101000797579 Homo sapiens E3 SUMO-protein ligase CBX4 Proteins 0.000 claims description 3
- 101001074629 Homo sapiens E3 SUMO-protein ligase PIAS2 Proteins 0.000 claims description 3
- 101000583444 Homo sapiens E3 SUMO-protein ligase PIAS3 Proteins 0.000 claims description 3
- 101000583450 Homo sapiens E3 SUMO-protein ligase PIAS4 Proteins 0.000 claims description 3
- 101000879619 Homo sapiens E3 ubiquitin-protein ligase CHIP Proteins 0.000 claims description 3
- 101000772959 Homo sapiens E3 ubiquitin-protein ligase E3D Proteins 0.000 claims description 3
- 101001009246 Homo sapiens E3 ubiquitin-protein ligase HACE1 Proteins 0.000 claims description 3
- 101000872880 Homo sapiens E3 ubiquitin-protein ligase HECTD1 Proteins 0.000 claims description 3
- 101000872865 Homo sapiens E3 ubiquitin-protein ligase HECTD3 Proteins 0.000 claims description 3
- 101000872869 Homo sapiens E3 ubiquitin-protein ligase HECW1 Proteins 0.000 claims description 3
- 101000872871 Homo sapiens E3 ubiquitin-protein ligase HECW2 Proteins 0.000 claims description 3
- 101000872516 Homo sapiens E3 ubiquitin-protein ligase HERC2 Proteins 0.000 claims description 3
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 claims description 3
- 101001083405 Homo sapiens E3 ubiquitin-protein ligase Hakai Proteins 0.000 claims description 3
- 101000636713 Homo sapiens E3 ubiquitin-protein ligase NEDD4 Proteins 0.000 claims description 3
- 101001023703 Homo sapiens E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 claims description 3
- 101001079867 Homo sapiens E3 ubiquitin-protein ligase RNF114 Proteins 0.000 claims description 3
- 101001107086 Homo sapiens E3 ubiquitin-protein ligase RNF4 Proteins 0.000 claims description 3
- 101000664952 Homo sapiens E3 ubiquitin-protein ligase SMURF2 Proteins 0.000 claims description 3
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 claims description 3
- 101000634991 Homo sapiens E3 ubiquitin-protein ligase TRIM33 Proteins 0.000 claims description 3
- 101000662670 Homo sapiens E3 ubiquitin-protein ligase Topors Proteins 0.000 claims description 3
- 101001018965 Homo sapiens E3 ubiquitin-protein ligase makorin-1 Proteins 0.000 claims description 3
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims description 3
- 101001030691 Homo sapiens F-box/WD repeat-containing protein 1A Proteins 0.000 claims description 3
- 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 claims description 3
- 101001058369 Homo sapiens Glucose-induced degradation protein 4 homolog Proteins 0.000 claims description 3
- 101000945438 Homo sapiens Kelch domain-containing protein 2 Proteins 0.000 claims description 3
- 101001091328 Homo sapiens Kelch-like protein 12 Proteins 0.000 claims description 3
- 101001049204 Homo sapiens Kelch-like protein 20 Proteins 0.000 claims description 3
- 101001045824 Homo sapiens Kelch-like protein 3 Proteins 0.000 claims description 3
- 101000650158 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP1 Proteins 0.000 claims description 3
- 101000650160 Homo sapiens NEDD4-like E3 ubiquitin-protein ligase WWP2 Proteins 0.000 claims description 3
- 101000644718 Homo sapiens NEDD8-conjugating enzyme UBE2F Proteins 0.000 claims description 3
- 101000644669 Homo sapiens NEDD8-conjugating enzyme Ubc12 Proteins 0.000 claims description 3
- 101001125496 Homo sapiens Pre-mRNA-processing factor 19 Proteins 0.000 claims description 3
- 101000872882 Homo sapiens Probable E3 ubiquitin-protein ligase HECTD2 Proteins 0.000 claims description 3
- 101000872867 Homo sapiens Probable E3 ubiquitin-protein ligase HECTD4 Proteins 0.000 claims description 3
- 101000872514 Homo sapiens Probable E3 ubiquitin-protein ligase HERC1 Proteins 0.000 claims description 3
- 101001035260 Homo sapiens Probable E3 ubiquitin-protein ligase HERC3 Proteins 0.000 claims description 3
- 101001035259 Homo sapiens Probable E3 ubiquitin-protein ligase HERC4 Proteins 0.000 claims description 3
- 101001035144 Homo sapiens Probable E3 ubiquitin-protein ligase HERC6 Proteins 0.000 claims description 3
- 101000573199 Homo sapiens Protein PML Proteins 0.000 claims description 3
- 101000692686 Homo sapiens RING finger protein 37 Proteins 0.000 claims description 3
- 101000574242 Homo sapiens RING-type E3 ubiquitin-protein ligase PPIL2 Proteins 0.000 claims description 3
- 101000825289 Homo sapiens SPRY domain-containing SOCS box protein 1 Proteins 0.000 claims description 3
- 101000825291 Homo sapiens SPRY domain-containing SOCS box protein 2 Proteins 0.000 claims description 3
- 101000825375 Homo sapiens SPRY domain-containing SOCS box protein 4 Proteins 0.000 claims description 3
- 101000939246 Homo sapiens SUMO-conjugating enzyme UBC9 Proteins 0.000 claims description 3
- 101000642268 Homo sapiens Speckle-type POZ protein Proteins 0.000 claims description 3
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims description 3
- 101000652226 Homo sapiens Suppressor of cytokine signaling 6 Proteins 0.000 claims description 3
- 101000808654 Homo sapiens Ubiquitin conjugation factor E4 A Proteins 0.000 claims description 3
- 101000809046 Homo sapiens Ubiquitin conjugation factor E4 B Proteins 0.000 claims description 3
- 101000807344 Homo sapiens Ubiquitin-conjugating enzyme E2 A Proteins 0.000 claims description 3
- 101000807337 Homo sapiens Ubiquitin-conjugating enzyme E2 B Proteins 0.000 claims description 3
- 101000807354 Homo sapiens Ubiquitin-conjugating enzyme E2 C Proteins 0.000 claims description 3
- 101000772904 Homo sapiens Ubiquitin-conjugating enzyme E2 D1 Proteins 0.000 claims description 3
- 101000772901 Homo sapiens Ubiquitin-conjugating enzyme E2 D2 Proteins 0.000 claims description 3
- 101000772913 Homo sapiens Ubiquitin-conjugating enzyme E2 D3 Proteins 0.000 claims description 3
- 101000644655 Homo sapiens Ubiquitin-conjugating enzyme E2 E1 Proteins 0.000 claims description 3
- 101000644653 Homo sapiens Ubiquitin-conjugating enzyme E2 E2 Proteins 0.000 claims description 3
- 101000644661 Homo sapiens Ubiquitin-conjugating enzyme E2 E3 Proteins 0.000 claims description 3
- 101000644657 Homo sapiens Ubiquitin-conjugating enzyme E2 G1 Proteins 0.000 claims description 3
- 101000761646 Homo sapiens Ubiquitin-conjugating enzyme E2 G2 Proteins 0.000 claims description 3
- 101000644682 Homo sapiens Ubiquitin-conjugating enzyme E2 H Proteins 0.000 claims description 3
- 101000761725 Homo sapiens Ubiquitin-conjugating enzyme E2 J1 Proteins 0.000 claims description 3
- 101000761723 Homo sapiens Ubiquitin-conjugating enzyme E2 J2 Proteins 0.000 claims description 3
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 claims description 3
- 101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 claims description 3
- 101000644684 Homo sapiens Ubiquitin-conjugating enzyme E2 N Proteins 0.000 claims description 3
- 101000761741 Homo sapiens Ubiquitin-conjugating enzyme E2 Q1 Proteins 0.000 claims description 3
- 101000808785 Homo sapiens Ubiquitin-conjugating enzyme E2 Q2 Proteins 0.000 claims description 3
- 101000808784 Homo sapiens Ubiquitin-conjugating enzyme E2 R1 Proteins 0.000 claims description 3
- 101000808789 Homo sapiens Ubiquitin-conjugating enzyme E2 R2 Proteins 0.000 claims description 3
- 101000837565 Homo sapiens Ubiquitin-conjugating enzyme E2 S Proteins 0.000 claims description 3
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 claims description 3
- 101000837580 Homo sapiens Ubiquitin-conjugating enzyme E2 U Proteins 0.000 claims description 3
- 101000837574 Homo sapiens Ubiquitin-conjugating enzyme E2 W Proteins 0.000 claims description 3
- 101000772891 Homo sapiens Ubiquitin-conjugating enzyme E2 Z Proteins 0.000 claims description 3
- 101000808753 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 1 Proteins 0.000 claims description 3
- 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 claims description 3
- 101000809090 Homo sapiens Ubiquitin-fold modifier-conjugating enzyme 1 Proteins 0.000 claims description 3
- 101000887051 Homo sapiens Ubiquitin-like-conjugating enzyme ATG3 Proteins 0.000 claims description 3
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 claims description 3
- 101000772955 Homo sapiens Ubiquitin-protein ligase E3B Proteins 0.000 claims description 3
- 101000772964 Homo sapiens Ubiquitin-protein ligase E3C Proteins 0.000 claims description 3
- 101000761740 Homo sapiens Ubiquitin/ISG15-conjugating enzyme E2 L6 Proteins 0.000 claims description 3
- 102100033609 Kelch domain-containing protein 2 Human genes 0.000 claims description 3
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 claims description 3
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 claims description 3
- 102100034855 Kelch-like protein 12 Human genes 0.000 claims description 3
- 102100023681 Kelch-like protein 20 Human genes 0.000 claims description 3
- 102100022101 Kelch-like protein 3 Human genes 0.000 claims description 3
- 102100021760 Magnesium transporter protein 1 Human genes 0.000 claims description 3
- 102100027550 NEDD4-like E3 ubiquitin-protein ligase WWP1 Human genes 0.000 claims description 3
- 102100027549 NEDD4-like E3 ubiquitin-protein ligase WWP2 Human genes 0.000 claims description 3
- 102100020694 NEDD8-conjugating enzyme UBE2F Human genes 0.000 claims description 3
- 102100020710 NEDD8-conjugating enzyme Ubc12 Human genes 0.000 claims description 3
- 102000012643 PPIL2 Human genes 0.000 claims description 3
- 102100029522 Pre-mRNA-processing factor 19 Human genes 0.000 claims description 3
- 102100034648 Probable E3 ubiquitin-protein ligase HECTD2 Human genes 0.000 claims description 3
- 102100034679 Probable E3 ubiquitin-protein ligase HECTD4 Human genes 0.000 claims description 3
- 102100034747 Probable E3 ubiquitin-protein ligase HERC1 Human genes 0.000 claims description 3
- 102100039910 Probable E3 ubiquitin-protein ligase HERC3 Human genes 0.000 claims description 3
- 102100039913 Probable E3 ubiquitin-protein ligase HERC4 Human genes 0.000 claims description 3
- 102100039921 Probable E3 ubiquitin-protein ligase HERC6 Human genes 0.000 claims description 3
- 108010038241 Protein Inhibitors of Activated STAT Proteins 0.000 claims description 3
- 102100026375 Protein PML Human genes 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 102100026249 RING finger protein 37 Human genes 0.000 claims description 3
- 101710178916 RING-box protein 1 Proteins 0.000 claims description 3
- 108091007602 SLC58A1 Proteins 0.000 claims description 3
- 102100022320 SPRY domain-containing SOCS box protein 1 Human genes 0.000 claims description 3
- 102100022330 SPRY domain-containing SOCS box protein 2 Human genes 0.000 claims description 3
- 102100022311 SPRY domain-containing SOCS box protein 4 Human genes 0.000 claims description 3
- 102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 claims description 3
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 claims description 3
- 102100036422 Speckle-type POZ protein Human genes 0.000 claims description 3
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 3
- 102100030529 Suppressor of cytokine signaling 7 Human genes 0.000 claims description 3
- 108091007283 TRIM24 Proteins 0.000 claims description 3
- 102100022011 Transcription intermediary factor 1-alpha Human genes 0.000 claims description 3
- 102000056723 UBE3C Human genes 0.000 claims description 3
- 101150056689 UBR2 gene Proteins 0.000 claims description 3
- 102000044159 Ubiquitin Human genes 0.000 claims description 3
- 108090000848 Ubiquitin Proteins 0.000 claims description 3
- 102100038532 Ubiquitin conjugation factor E4 A Human genes 0.000 claims description 3
- 102100038487 Ubiquitin conjugation factor E4 B Human genes 0.000 claims description 3
- 102100037261 Ubiquitin-conjugating enzyme E2 A Human genes 0.000 claims description 3
- 102100037262 Ubiquitin-conjugating enzyme E2 B Human genes 0.000 claims description 3
- 102100037256 Ubiquitin-conjugating enzyme E2 C Human genes 0.000 claims description 3
- 102100030433 Ubiquitin-conjugating enzyme E2 D1 Human genes 0.000 claims description 3
- 102100030439 Ubiquitin-conjugating enzyme E2 D2 Human genes 0.000 claims description 3
- 102100030425 Ubiquitin-conjugating enzyme E2 D3 Human genes 0.000 claims description 3
- 102100020711 Ubiquitin-conjugating enzyme E2 E1 Human genes 0.000 claims description 3
- 102100020704 Ubiquitin-conjugating enzyme E2 E2 Human genes 0.000 claims description 3
- 102100020709 Ubiquitin-conjugating enzyme E2 E3 Human genes 0.000 claims description 3
- 102100020712 Ubiquitin-conjugating enzyme E2 G1 Human genes 0.000 claims description 3
- 102100024870 Ubiquitin-conjugating enzyme E2 G2 Human genes 0.000 claims description 3
- 102100020698 Ubiquitin-conjugating enzyme E2 H Human genes 0.000 claims description 3
- 102100024860 Ubiquitin-conjugating enzyme E2 J1 Human genes 0.000 claims description 3
- 102100024863 Ubiquitin-conjugating enzyme E2 J2 Human genes 0.000 claims description 3
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 claims description 3
- 102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 claims description 3
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 claims description 3
- 102100024846 Ubiquitin-conjugating enzyme E2 Q1 Human genes 0.000 claims description 3
- 102100038500 Ubiquitin-conjugating enzyme E2 Q2 Human genes 0.000 claims description 3
- 102100038466 Ubiquitin-conjugating enzyme E2 R1 Human genes 0.000 claims description 3
- 102100038499 Ubiquitin-conjugating enzyme E2 R2 Human genes 0.000 claims description 3
- 102100028718 Ubiquitin-conjugating enzyme E2 S Human genes 0.000 claims description 3
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 claims description 3
- 102100028710 Ubiquitin-conjugating enzyme E2 U Human genes 0.000 claims description 3
- 102100028700 Ubiquitin-conjugating enzyme E2 W Human genes 0.000 claims description 3
- 102100030441 Ubiquitin-conjugating enzyme E2 Z Human genes 0.000 claims description 3
- 102100038467 Ubiquitin-conjugating enzyme E2 variant 1 Human genes 0.000 claims description 3
- 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 claims description 3
- 102100038483 Ubiquitin-fold modifier-conjugating enzyme 1 Human genes 0.000 claims description 3
- 102100039930 Ubiquitin-like-conjugating enzyme ATG3 Human genes 0.000 claims description 3
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 claims description 3
- 102100030429 Ubiquitin-protein ligase E3B Human genes 0.000 claims description 3
- 102100024843 Ubiquitin/ISG15-conjugating enzyme E2 L6 Human genes 0.000 claims description 3
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 3
- 229950009563 avadomide Drugs 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 229950009627 iberdomide Drugs 0.000 claims description 3
- 101150024228 mdm2 gene Proteins 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 102000045222 parkin Human genes 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- 108010062219 ran-binding protein 2 Proteins 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 102200022340 rs200412910 Human genes 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 102100038631 E3 ubiquitin-protein ligase SMURF1 Human genes 0.000 claims description 2
- 101000664993 Homo sapiens E3 ubiquitin-protein ligase SMURF1 Proteins 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 11
- 102100028093 E3 ubiquitin-protein ligase TRIP12 Human genes 0.000 claims 1
- 108091007076 TRIP12 Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 2
- 230000011664 signaling Effects 0.000 abstract description 2
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 description 496
- 125000004433 nitrogen atom Chemical group N* 0.000 description 357
- 125000004430 oxygen atom Chemical group O* 0.000 description 340
- 125000003118 aryl group Chemical group 0.000 description 192
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 58
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 description 52
- 125000004043 oxo group Chemical group O=* 0.000 description 51
- 150000001413 amino acids Chemical group 0.000 description 37
- 239000003112 inhibitor Substances 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 31
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 22
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 20
- 125000005842 heteroatom Chemical group 0.000 description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 18
- 101150105104 Kras gene Proteins 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 14
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 12
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 125000003367 polycyclic group Chemical group 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000006574 non-aromatic ring group Chemical group 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 7
- 101100330286 Caenorhabditis elegans cysl-2 gene Proteins 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 239000001301 oxygen Chemical group 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000011593 sulfur Chemical group 0.000 description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 102100039788 GTPase NRas Human genes 0.000 description 5
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 5
- 101001130465 Homo sapiens Ras-related protein Ral-A Proteins 0.000 description 5
- 101001130458 Homo sapiens Ras-related protein Ral-B Proteins 0.000 description 5
- 102100031424 Ras-related protein Ral-A Human genes 0.000 description 5
- 102100031425 Ras-related protein Ral-B Human genes 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100029974 GTPase HRas Human genes 0.000 description 4
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 102200006538 rs121913530 Human genes 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100022871 GTPase ERas Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Chemical group 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 102200006539 rs121913529 Human genes 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 101100330289 Caenorhabditis elegans cysl-3 gene Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102100032274 E3 ubiquitin-protein ligase TRAIP Human genes 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100025477 GTP-binding protein Rit1 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091093094 Glycol nucleic acid Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 101000798079 Homo sapiens E3 ubiquitin-protein ligase TRAIP Proteins 0.000 description 2
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 2
- 101000620820 Homo sapiens GTPase ERas Proteins 0.000 description 2
- 101001017828 Homo sapiens Leucine-rich repeat flightless-interacting protein 1 Proteins 0.000 description 2
- 101000744515 Homo sapiens Ras-related protein M-Ras Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 102100039789 Ras-related protein M-Ras Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 108091046915 Threose nucleic acid Proteins 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 102200006657 rs104894228 Human genes 0.000 description 2
- 102200006532 rs112445441 Human genes 0.000 description 2
- 102200006541 rs121913530 Human genes 0.000 description 2
- 102220197834 rs121913535 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HVIGNZUDBVLTLU-MRXNPFEDSA-N (6R)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C[C@@H]2COC)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1F HVIGNZUDBVLTLU-MRXNPFEDSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 description 1
- AMADCPJVPLUGQO-UHFFFAOYSA-N 1-[3-(2,3-dichlorophenyl)-2H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methylpiperidin-4-amine Chemical compound ClC1=C(C=CC=C1Cl)C1=NNC2=NC(=CN=C21)N1CCC(CC1)(N)C AMADCPJVPLUGQO-UHFFFAOYSA-N 0.000 description 1
- HGYTYZKWKUXRKA-MRXNPFEDSA-N 1-[4-[3-amino-5-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]sulfanyl-3,3-difluoro-2H-indol-1-yl]ethanone Chemical compound NC=1C(=NC=C(N=1)N1CCC2([C@@H](COC2)N)CC1)SC1=C2C(CN(C2=CC=C1)C(C)=O)(F)F HGYTYZKWKUXRKA-MRXNPFEDSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- ILPWEAHQRAWJIU-OAHLLOKOSA-N 2-methyl-3-[(1R)-1-[(4-methyl-7-morpholin-4-ylpyrido[3,4-d]pyridazin-1-yl)amino]ethyl]benzonitrile Chemical compound C[C@@H](NC1=NN=C(C)C2=CN=C(C=C12)N1CCOCC1)C1=CC=CC(C#N)=C1C ILPWEAHQRAWJIU-OAHLLOKOSA-N 0.000 description 1
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
- JNPRPMBJODOFEC-UHFFFAOYSA-N 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one Chemical compound CC1(N(C(C2=C1SC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)=O)CCN1CCOCC1)C JNPRPMBJODOFEC-UHFFFAOYSA-N 0.000 description 1
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- 229940125927 AZD0364 Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 229940125795 BI-3406 Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 101100387225 Buchnera aphidicola subsp. Baizongia pistaciae (strain Bp) asd gene Proteins 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- WEGLOYDTDILXDA-OAHLLOKOSA-N CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 Chemical compound CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 WEGLOYDTDILXDA-OAHLLOKOSA-N 0.000 description 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 101710197172 GTPase ERas Proteins 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000868154 Homo sapiens Son of sevenless homolog 2 Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- KPQQGHGDBBJGFA-QNGWXLTQSA-N MK-8353 Chemical compound C([C@@](C1)(SC)C(=O)NC=2C=C3C(C=4C=NC(OC(C)C)=CC=4)=NNC3=CC=2)CN1CC(=O)N(CC=1)CCC=1C(C=C1)=CC=C1C=1N=CN(C)N=1 KPQQGHGDBBJGFA-QNGWXLTQSA-N 0.000 description 1
- 229940126270 MRTX0902 Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101150093978 RALB gene Proteins 0.000 description 1
- 101150020518 RHEB gene Proteins 0.000 description 1
- 229940125999 RMC-4550 Drugs 0.000 description 1
- 229940126002 RMC-4630 Drugs 0.000 description 1
- 101150033538 Rala gene Proteins 0.000 description 1
- 102000046951 Ras Homolog Enriched in Brain Human genes 0.000 description 1
- 108700019578 Ras Homolog Enriched in Brain Proteins 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 description 1
- 102100022340 SHC-transforming protein 1 Human genes 0.000 description 1
- 108091007062 SMURFs Proteins 0.000 description 1
- 229940126271 SOS1 inhibitor Drugs 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 102100032930 Son of sevenless homolog 2 Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 1
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 125000005361 aryl sulfoxide group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ILAJWURWJKXJPW-UHFFFAOYSA-N butanedioic acid;octanedioic acid Chemical class OC(=O)CCC(O)=O.OC(=O)CCCCCCC(O)=O ILAJWURWJKXJPW-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229950001969 encorafenib Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000006341 heptafluoro n-propyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229950000778 olmutinib Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 108010005597 ran GTP Binding Protein Proteins 0.000 description 1
- 229950007231 ravoxertinib Drugs 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229950008878 ulixertinib Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Cancer e.g., tumor, neoplasm, metastases
- K-Ras Kirsten Ras oncogene
- PD AC pancreatic ductal adenocarcinoma
- Ras proteins have long been considered to be “undruggable,” due to, in part, high affinity to their substrate Guanosine-5'-triphosphate (GTP) and/or their smooth surfaces without any obvious targeting region.
- GTP Guanosine-5'-triphosphate
- Recently, a specific G12C Ras gene mutation has been identified as a potential draggable target.
- such therapeutic approach is still limiting, as the G12C mutation in Ras has a low prevalence rate (e.g., about 3% in PD AC) as compared to other known Ras mutations.
- compositions and methods can be particularly useful for treating a variety of the diseases including, but not limited to, cancers and neoplasia conditions.
- the present disclosure addresses these needs, and provides additional advantages applicable for diagnosis, prognosis, and treatment for a wide diversity of diseases.
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 17 ) and J is C(R 16 ), or V is C(R 17 ) and J is N, or J is C(R 17 ) and V is C(R 16 ), or J is C(R 17 ) and V is N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, - N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, Ci-C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, wherein Ci-Cealkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl, are optionally substituted with one, two, or three R 20a ; R 7 is a 3-12 membered nitrogen containing heterocycloalkyl or 5-12 membered nitrogen containing heteroaryl, wherein the 3-12 membered nitrogen containing heterocyclo
- R 4 is optionally an electrophilic moiety capable of forming a covalent bond with a cysteine, serine, or aspartate residue at an amino acid position corresponding to 12 or 13 of a human KRAS protein), wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-9heteroaryl are optionally substituted with one, two, or three R 20a ;
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, Ci-Cealkyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, - S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, -N(R 14 )C(0)0-, and - N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci- 9 heteroaryl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0) 2 R 15 , -
- R 17 is -lA-R 19 ;
- L 1 is selected from a bond, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, -
- ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201 ; or R lf and R lg are joined to form a 4-7 membered heterocycloalkyl ring or a 4-7 membered cycloalkyl ring, wherein the 4-7 membered heterocycloalkyl ring or 4-7 membered cycloalkyl ring are optionally substituted with one, two, or three R 201 ;
- R lc is selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-9heteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-9heteroaryl are optionally substituted with one, two, or three R 201 R 19 is selected from a C3-i2cycloalkyl (e.g., monocyclic, bicyclic, or polycyclic), C2-iiheterocycloalkyl (e.g., monocyclic, bicyclic, or polycyclic), C6-i2aryl (e.g., monocyclic, bicyclic, or polycyclic), and C2-i2heteroaryl (e
- R 16 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2- gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0)
- Ci- 6alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 20d ;
- R 12a is selected from Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2-9heterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH2-Ci-9heteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2-9heterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -G5-ioaryl, -CH 2 -Ci-9heteroaryl, and Ci-dictcro
- R 12b is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -CH 2 -C3-iocycloalkyl, C 2. gheterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -Ci-9heteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -CH 2 -C3-iocycloalkyl, C 2 -9heterocycloalkyl, -CH 2 - C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, Ce-ioaryl, Ci- 9 heteroaiyl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0) 2 R
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, -CH 2 -C3-
- gheterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -Ci-9heteroaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three groups independently selected from halogen, oxo, -CN, Ci- 6 alkyl, Ci-ehaloalkyl, Ci- 6 alkoxy, Ci- 6 haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(0)0R 22 , -C(0)N(R 22 )(R 23 ), - C(0)C(0)N(R 22 )(R 23 ), -0C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)0
- each R 22 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2- siheterocycloalkyl, C 6 -ioaryl, and Ci-dictcroaryl: each R 23 is independently selected from H and Ci- 6 alkyl; each R 24 is independently selected from H and Ci- 6 alkyl; each R 25 is independently selected from Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, Ce- ioaryl, and Ci-gheteroaryl; and indicates a single or double bond such that all valences are satisfied.
- X is C(R 3 ). In embodiments, X is N. In embodiments, J is C(R 16 ) and V is C(R 17 ). In embodiments, W is C(O).
- the compound, or a pharmaceutically acceptable salt or solvate thereof has the structure: , , , Formula (IA12). [0008] In embodiments, the compound, or a pharmaceutically acceptable salt or solvate thereof, has the structure:
- the compound, or a pharmaceutically acceptable salt or solvate thereof has the structure:
- L 7 is a bond. [0011] In embodiments, L 7 is -NH-.
- R 7 is a 3-12 membered nitrogen containing heterocycloalkyl, wherein the 3-12 membered nitrogen containing heterocycloalkyl is optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; and wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i 2 cycloalkyl, Ci- li heterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl, wherein the C3-i 2 cycloalkyl, Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci- nheteroaryl are optionally substituted with one, two, or three R 20a .
- R 16 is independently selected from hydrogen and halogen. In embodiments, R 16 is independently selected from hydrogen and fluoro.
- R 8 is selected from Ci- 6 alkyl, C3-iocycloalkyl, and C2-s > heterocycloalkyl, wherein Ci- 6 alkyl, C3-iocycloalkyl, and C2-s > heterocycloalkyl are optionally substituted with one, two, or three R 20c independently selected from halogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, and C2-9heterocycloalkyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl, wherein said methyl, cyclopropyl, cyclobutyl, and oxetanyl are optionally substituted with one, two, or three R 20c independently selected from fluoro, methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 3 is hydrogen or CN.
- L 1 is a bond.
- L 1 is selected from a Ci-Cealkyl, C2-C6alkenyl, C2- Cealkynyl, -C(O)-, -NHC(O)-, -C(0)NH-, CH 2 0, CH 2 NH, and CH 2 .
- R 19 is a monocyclic ring. In embodiments, R 19 is a bicyclic ring system. In embodiments, R 19 is a polycyclic ring system.
- Q 1 , Q 3 , and Q 5 are independently N or C(R ld );
- Q 4 and Q 6 are independently O, S, C(R la )(R lb ), or N(R lc );
- X 4 , X 5 , X 6 , X 9 , X 10 , X 11 , X 12 , and X 16 are independently selected from C(R la ) or N;
- X 7 and X 8 are independently selected from C(R la ), C(R la )(R lb ), N, or N(R lc );
- X 13 is selected from a bond, C(O), C(R la )(R lb ), C(0)C(R la )(R lb ), C(R la )(R lb )C(R la )(R lb ), C(R la )(R lb )N(R lc ), and N(R lc );
- X 14 and X 15 are independently selected from a bond, C(O), C(R la )(R lb ), and N(R lc ); each R la , R lb , R ld , R lf , R lg , and R lh are each independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci-dictcroarvl.
- C 6 -ioaryl, and Cj-dictcroaryl are optionally substituted with one, two, or three R 201 ; or R la and R lb bonded to the same carbon are joined to form a 3-10 membered heterocycloalkyl ring or a C3-iocycloalkyl ring, wherein the 3-10 membered heterocycloalkyl ring or C3-iocycloalkyl ring are optionally substituted with one, two, or three R 201 ; or two R la bonded to adjacent atoms are joined to form a 3-10 membered heterocycloalkyl ring, a C 6 -ioaryl ring, a 5-12 membered heteroaryl ring, or a C3-iocycloalkyl ring, wherein the 3-10 membered heterocycloalkyl ring, C 6 -ioaryl ring, 5-12 membered heteroaryl ring, or C3-iocycloalkyl ring
- C 6 -ioaryl, and Cj-dictcroaryl are optionally substituted with one, two, or three R 201 .
- each L 2 is independently a bond.
- each R 5 is independently selected from:
- R 4 is independently -C(0)R 15 .
- R 4 is independently -C(0)R 15 and the R 15 is independently selected from C 2-6 alkenyl, C 2-6 alkynyl, C 2 -9heterocycloalkyl, and CiActcroaryl. wherein C 2. 6 alkenyl, C 2-6 alkynyl, C 2 -9heterocycloalkyl, and CiAeteroaryl are optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and the R 15 is independently C 2-6 alkenyl, wherein C 2-6 alkenyl is optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and the R 15 is independently C 2 -9heterocycloalkyl, wherein C 2 -9heterocycloalkyl is optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and the R 15 is independently CiAeteroaryl, wherein Ci- gheteroaryl is optionally substituted with one, two, or three R 20f .
- R 4 is an electrophilic moiety capable of forming a covalent bond with a cysteine, serine, or aspartate residue at an amino acid position corresponding to 12 or 13 of a human KRAS protein.
- A is a monovalent form of a compound described herein;
- L AB is a covalent linker bonded to A and B; and
- B is a monovalent form of a degradation enhancer.
- the degradation enhancer is capable of binding a protein selected from E3A, mdm2, APC, EDD1, SOCS/BC-box/eloBC/CUL5/RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP 12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-
- ubiquitin ligase XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBX04, FBX031, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, avadomide, iberdomide, and CC-885.
- the compound of claim 74 wherein the degradation enhancer is capable of binding a protein selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE20, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1.
- a protein selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, U
- L AB is -L AB1 -L AB2 -L AB3 -L AB4 -L AB5 -; L AB I . IT 02 .
- L ab ⁇ L AB and L ABS are independently a bond, -O-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, - N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, Ci- 6 alkylene, (-0-Ci- 6 alkyl) z -, (-Ci- 6 alkyl-0) z -, C 2-6 alkenylene, C 2-6 alkynylene, Ci- 6 haloalky
- narylene, or Ci-nheteroarylene are optionally substituted with one, two, or three R 20j ; wherein each Ci- 6 alkyl of (-0-Ci- 6 alkyl) z - and (-Ci- 6 alkyl-0) z - is optionally substituted with one, two, or three R 20j ; z is independently an integer from 0 to 10; each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, G- 6cycloalkyl, -CH2-C3-6cycloalkyl, C2-9heterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 - Ci-9heteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alky
- Ci-9heteroaryl are optionally substituted with one, two, or three groups independently selected from halogen, oxo, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 alkoxy, Ci- 6 haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), - C(0)0R 22 , -C(0)N(R 22 )(R 23 ), -C(0)C(0)N(R 22 )(R 23 ), -0C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)N(R 22 )
- L AB is -(0-C 2 alkyl) z - and z is an integer from 1 to 10. In embodiments, L AB is -(C 2 alkyl-0-) z - and z is an integer from 1 to 10. In embodiments, L AB is -(CH 2 ) Z IL AB2 (CH 2 0) Z2 -, wherein L Ali2 is a bond, a 5 or 6 membered heterocycloalkylene or heteroarylene, phenylene, -(C2-
- L AB is -(CH 2 ) zi (CH 2 0) z2 -, wherein zl and z2 are each independently an integer from 0 to 10.
- L AB is a PEG linker.
- B is a monovalent form of a compound selected from
- a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
- a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof.
- a method of modulating activity of a Ras protein comprising contacting a Ras protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, thereby modulating the activity of the Ras protein.
- the method includes administering an additional agent or therapy.
- a method of inhibiting cell growth comprising administering an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, to a cell expressing a Ras protein, thereby inhibiting growth of said cells.
- the method includes administering an additional agent to said cell.
- the additional agent comprises (1) an inhibitor of MEK; (2) an inhibitor of epidermal growth factor receptor (EGFR) and/or of mutants thereof; (3) an immunotherapeutic agent; (4) a taxane; (5) an anti-metabolite; (6) an inhibitor of FGFR1 and/or FGFR2 and/or FGFR3 and/or of mutants thereof; (7) a mitotic kinase inhibitor; (8) an anti-angiogenic drag; (9) a topoisomerase inhibitor; (10) a platinum-containing compound; (12) an inhibitor of c-MET and/or of mutants thereof; (13) an inhibitor of BCR-ABL and/or of mutants thereof; (14) an inhibitor of ErbB2 (Her2) and/or of mutants thereof; (15) an inhibitor of AXL and/or of mutants thereof; (16) an inhibitor of NTRK1 and/or of mutants thereof; (17) an inhibitor of RET and/or of mutants thereof; (18) an inhibitor of A-Raf and or
- the additional agent comprises an inhibitor of SHP2 selected from RMC-4630, TN0155, JAB-3068, IACS-13909/BBP-398, SHP099, ERAS-601, and RMC-4550.
- the additional agent comprises an inhibitor of SOS selected from RMC-5845, BI-3406, BI-1701963, MRTX0902, and BAY 293.
- the additional agent comprises an inhibitor of EGFR selected from afatinib, erlotinib, gefitinib, lapatinib, cetuximab panitumumab, osimertinib, olmutinib, and EGF-816.
- the additional agent comprises an inhibitor of MEK selected from trametinib, cobimetinib, binimetinib, selumetinib, refametinib, and AZD6244.
- the additional agent comprises an inhibitor of ERK selected from ulixertinib, MK-8353, LTT462, AZD0364, SCH772984, BIX02189, LY3214996, and ravoxertinib.
- the additional agent comprises an inhibitor of CDK4/6 selected from palbociclib, ribociclib, and abemaciclib.
- the additional agent comprises an inhibitor of BRAF selected from sorafenib, vemurafenib, dabrafenib, encorafenib, regorafenib, and GDC-879.
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 17 ) and J is C(R 16 ), or V is C(R 17 ) and J is N, or J is C(R 17 ) and V is C(R 16 ), or J is C(R 17 ) and V is N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- R 7 is a 3-12 membered nitrogen containing heterocycloalkyl or 5-12 membered nitrogen containing heteroaryl, wherein the 3-12 membered nitrogen containing heterocycloalkyl or 5-12 membered nitrogen containing heteroaryl are optionally substituted with one or more R 1 , one or more R 4 , or one or more R 6 ; wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i2cycloalkyl, Ci-nheterocycloalkyl, C6-i2aryl, or Ci-nheteroaryl, wherein the C3-i2cycloalkyl, Ci-nheterocycloalkyl, C6-i2aryl, or Ci-nheteroaryl are optionally substituted with one, two, or three R 20a ; each R 1 is independently selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, Ci-Cealkyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2- gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0) 2 R
- R 17 is -LkR 19 ;
- L 1 is selected from a bond, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ), and C(R
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), - C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , - S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )
- R lc is selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, G,. ioaryl, and Ci-dictcroaiyl. wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201
- R 19 is selected from a C3-i2cycloalkyl, C2-nheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl, wherein the G- ncycloalkyl, C2-iiheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, G- 6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , - 0C(0)N(R 12 )(R 13
- R 16 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, G- gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0)
- R 12a is selected from Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH2-Ci-9heteroaryl, and Ci- gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH2-Ci-9heteroaryl, and Ci-
- R 12b is selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CEC-Ci-gheteroaryl, and Ci- gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CEC-Ci-ghetero
- X is C(R 3 ) or N; R 3 is selected from hydrogen, halogen, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci-yhctcroan l.
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -C 1 - gheteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C
- Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 20f ; each R 20a , R 20b , R 20c , R 20d , R 20e , R 20f , R 20g , and R 201 are each independently selected from halogen, -CN, Ci- 6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2 - gheterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl,
- X is C(R 3 ). In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, X is N. [0040] In further embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof,
- V is C(R 16 ) and J is C(R 17 ). In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, V is N and J is C(R 17 ). In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, J is N and V is C(R 17 ). In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, J is C(R 16 ) and V is C(R 17 ). In lurther embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is C(O). In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is S(O). In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is S(0) 2 .
- the compound has the structure:
- the compound has the structure: ), , 12).
- L 7 is a bond. In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, L 7 is -NH-.
- R 7 is a 3-12 membered nitrogen containing heterocycloalkyl, wherein the 3-12 membered nitrogen containing heterocycloalkyl is optionally substituted with one or more R 1 , one or more R 4 , or one or more R 6 ; and wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i2cycloalkyl, Ci-nheterocycloalkyl, C6-i2aryl, or Ci-nheteroaryl, wherein the C3-i2cycloalkyl, Ci- li heterocycloalkyl, C6-i2aryl, or Ci-nheteroaryl are optionally substituted with one, two, or three R 20a .
- R 7 is
- R 7 is integer from 0 to 12.
- R 7 In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 7
- R 16 is independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, and C3- 6 cycloalkyl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, and C3-6cycloalkyl are optionally substituted with one, two, or three R 20g .
- R 16 is independently selected from hydrogen and halogen.
- R 16 is independently selected from hydrogen and fluoro.
- R 8 is selected from halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci- 9 heteroaiyl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)OR 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -OC(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ),
- R 8 is selected from Ci- 6 alkyl, C3-iocycloalkyl, and C2-9heterocycloalkyl, wherein Ci- 6 alkyl, C3-iocycloalkyl, and C2- gheterocycloalkyl are optionally substituted with one, two, or three R 20c independently selected from halogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, and C2-9heterocycloalkyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl, wherein said methyl, cyclopropyl, cyclobutyl, and oxetanyl are optionally substituted with one, two, or three R 20c independently selected from fluoro, methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 3 is hydrogen or CN. In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 3 is hydrogen.
- L 1 is a bond. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, L 1 is selected from a Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C(O)-, -NHC(O)-, -C(0)NH-, CH 2 0, CH 2 NH, and CH 2 .
- R 19 is a monocyclic ring. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is a bicyclic ring system. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is a polycyclic ring system. In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is:
- Q 1 , Q 3 , and Q 5 are independently N or C(R ld );
- Q 4 and Q 6 are independently O, S, C(R la )(R lb ), or N(R lc );
- X 4 , X 5 , X 6 , X 9 , X 10 , X 11 , and X 12 are independently selected from C(R la ) or N;
- X 7 and X 8 are independently selected from C(R la ), C(R la )(R lb ), N, or N(R lc ); each R la , R lb , R ld , and R lh are each independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-dictcroaiyl.
- Ci-dictcroaiyl wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2- dictcrocycloalkyl.
- C 6 -ioaryl, and Cj-dictcroaryl are optionally substituted with one, two, or three R 201 .
- R 2 is [0057] In further embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, each R 5 is independently selected from:
- V is C(R 16 ) or N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- R 7 is a 3-12 membered heterocycloalkyl or 5-12 membered heteroaryl, wherein the 3-12 membered heterocycloalkyl or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , one or more R 4 , or one or more R 6 ; two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i 2 cycloalkyl, Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl, wherein the C3- i 2 cycloalkyl.
- Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl are optionally substituted with one, two, or three R 20a ; each R 1 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci- 6 haloalkyl, C3- i 2 cycloalkyl.
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, G-Galkyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0) 2 R
- R 17 is -G-R 19 ;
- L 1 is selected from a bond, G-Galkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ), and
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-dictcroarvl.
- gheterocycloalkyl, C 6 -ioaryl, and Ci-dictcroarvl are optionally substituted with one, two, or three R 201 ; or R lf and R lg are joined to form a 4-7 membered heterocycloalkyl ring or a 4-7 membered cycloalkyl ring, wherein the 4-7 membered heterocycloalkyl ring or 4-7 membered cycloalkyl ring are optionally substituted with one, two, or three R 201 ;
- R lc is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, CV,. ioaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201
- R 19 is selected from a C3-i 2 cycloalkyl, C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl, wherein the C3- i 2 cycloalkyl.
- C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3- 6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , - 0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)
- R 16 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0)
- R 12a is selected from Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -CH 2 -C3-iocycloalkyl, C 2. gheterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -Ci-9heteroaryl, and Ci- yhctcroan l.
- R 12b is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -CH 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -Ci- 9 heteroaryl, and Ci- gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -CH 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl,
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 ,
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -C 1 - gheteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -io
- Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 20f ; each R 20a , R 20b , R 20c , R 20d , R 20e , R 20f , R 20g , and R 201 are each independently selected from halogen, -CN, Ci- 6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2 - gheterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl,
- X is C(R 3 ). In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, X is N. [0060] In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, V is C(R 16 ). In further embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, V is N.
- W is C(O). In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is S(O). In lurther embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is S(0) 2 .
- the compound has the structure: , Formula Formula (IIA9), Formula (IIA10), Formula (IIA11), or Formula (IIA12).
- L 7 is a bond. In further embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, L 7 is -NH-.
- R 7 is a 3-12 membered heterocycloalkyl, wherein the 3-12 membered heterocycloalkyl is optionally substituted with one or more R 1 , one or more R 4 , or one or more R 6 ; and wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i2cycloalkyl, Ci- l i heterocycloalkyl, C6-i2aryl, or Ci-iiheteroaryl, wherein the C3-i2cycloalkyl, Ci-iiheterocycloalkyl, C6-i2aryl, or Ci- nheteroaryl are optionally substituted with one, two, or three R 20a .
- p is an integer from 0 to 12;
- X 2 is selected from N, C, C(R 6 ), C(R 4 ), CH, N(R'). N(R 4 ), N(R 6 ), O, S, S(O), C(H)(R 6 ), C(R 4 ) 2 , CH 2 , C(R 4 )(R 6 ),
- X 3 is selected from N, C, C(R 6 ), and C(R 4 ).
- R 7 In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 7
- R 7 integer from 0 to 12.
- R 7 In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 7
- R 16 is independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, and C3-6cycloalkyl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, and C3-6cycloalkyl are optionally substituted with one, two, or three R 20g .
- R 16 is independently selected from hydrogen and halogen.
- R 16 is independently selected from hydrogen and fluoro.
- R 8 is selected from halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci- 9 heteroaiyl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -C(0)C
- R 8 is selected from Ci- 6 alkyl, C3-iocycloalkyl, and C2-9heterocycloalkyl, wherein Ci- 6 alkyl, C3-iocycloalkyl, and C2- gheterocycloalkyl are optionally substituted with one, two, or three R 20c independently selected from halogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, and C2-9heterocycloalkyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl, wherein said methyl, cyclopropyl, cyclobutyl, and oxetanyl are optionally substituted with one, two, or three R 20c independently selected from fluoro, methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, oxetanylmethyl, and oxetanyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 3 is hydrogen or CN. In further embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 3 is hydrogen.
- L 1 is a bond. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, L 1 is selected from a Ci-Cealkyl, C2-C6alkenyl, C2-Cealkynyl, -C(O)-, -NHC(O)-, -C(0)NH-, CH 2 0, CH 2 NH, and CH 2 .
- R 19 is a monocyclic ring. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is a bicyclic ring system. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is a polycyclic ring system. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is:
- Q 1 , Q 3 , and Q 5 are independently N or C(R ld );
- Q 4 and Q 6 are independently O, S, C(R la )(R lb ), or N(R lc );
- X 4 , X 5 , X 6 , X 9 , X 10 , X 11 , and X 12 are independently selected from C(R la ) or N;
- X 7 and X 8 are independently selected from C(R la ), C(R la )(R lb ), N, or N(R lc ); each R la , R lb , R ld , and R lh are each independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci-dictcroaiyl.
- Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2- siheterocycloalkyl, C 6 -ioaryl, and Cj-dictcroaryl are optionally substituted with one, two, or three R 201 .
- R 19 is: [0076] In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 2
- each R 5 is independently selected from:
- A is a monovalent form of a compound of Formula I, IA1, IA2, IA3, IA4, IA5, IA6, IA7, IA8, IA9, IA10, IA11, IA12, II, IIA1, IIA2, IIA3, IIA4, IIA5, IIA6, IIA7, IIA8, IIA9, IIA10, IIA11, IIA12, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, or XV;
- L AB is a covalent linker bonded to A and B; and B is a monovalent form of a degradation enhancer.
- the degradation enhancer is capable of binding a protein selected from E3A, mdm2, APC, EDD1, SOCS/BC-box/eloBC/CUL5/RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF 1, SMURF2, STUB1, TOPORS, TRIP 12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel- Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MK
- the degradation enhancer is capable of binding a protein selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE20, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1.
- a protein selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E
- L AB is -L AB I -L AB1 -L AB, -L AB I -L AB5 -: independently a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, - )N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, Ci- 6 alkylene, (-0-Ci.
- R 20e each are each independently selected from halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6c loalkyl, C 2 -9heterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, - CH 2 - roaiyl, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(0)0R 22 , -C(0)N(R 22 )(R 23 ), - C(0) 0)N(R 22 )(R 23 ), -N(R 24 )C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)0R 25 , -N(R 24 )C(0)R 25 , -N(R 24 )S(0) 2 R 25 , -
- ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -Ci-9heteroaryl, and GAeteroaryl are optionally substituted with one, two, or three groups independently selected from halogen, oxo, -CN, CXalkyl, Ci- 6 haloalkyl, Ci- 6 alkoxy, Ci- 6 haloalkoxy, -OR 21 , - SR 21 , -N(R 22 )(R 23 ), -C(0)0R 22 , -C(0)N(R 22 )(R 23 ), -C(0)C(0)N(R 22 )(R 23 ), -0C(0)N(R 22 )(R 23 ), - N(R 24 )C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)0R 25 , -N(R 24 )C(0)R 25 , -N(R 24 )S(0) 2 R 25 ,
- each R 22 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2.
- each R 23 is independently selected from H and Ci- 6 alkyl
- each R 24 is independently selected from H and Ci- 6 alkyl
- each R 25 is selected from Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, and G- gheteroaryl.
- L AB is -(0-C 2 alkyl) z - and z is an integer from 1 to 10.
- L AB is -(C 2 alkyl-0-) z - and z is an integer from 1 to 10.
- L AB is -(CH 2 ) Z IL AB2 (CH 2 0) z2 -, wherein L Ali2 is a bond, a 5 or 6 membered heterocycloalkylene or heteroarylene, phenylene, -(C 2 -C4)alkynylene, -S0 2 - or -NH-; and zl and z2 are independently an integer from 0 to 10.
- L AB is -(CH 2 ) Z I(CH 2 0) /2 -. wherein zl and z2 are each independently an integer from 0 to 10.
- L AB is a PEG linker (e.g., divalent linker of 1 to 10 ethylene glycol subunits).
- B is a monovalent form of a compound selected from
- a pharmaceutical composition comprising a compound described herein (e.g., compound of Formula I, IA1, IA2, IA3, IA4, IA5, IA6, IA7, IA8, IA9, IA10, IA11, IA12, II, IIA1, IIA2, IIA3, IIA4, IIA5, IIA6, IIA7, IIA8, IIA9, IIA10, IIA11, IIA12, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, or XV; compound of Formula G, IF, I”, II”, 1-1, 1-G, 1-1”, I-G”, 1-3, 1-4, II- 1, XVI, XVII, XVIII, or XIX), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
- a compound described herein e.g., compound of Formula I, IA1, IA2, IA3, IA
- a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound described herein (e.g., compound of Formula I, IA1, IA2, 1 A3, IA4, IA5, IA6, IA7, IA8, IA9, IA10, IA11, IA12, II, IIA1, IIA2, IIA3, IIA4, IIA5, IIA6, IIA7, IIA8, IIA9, IIA10, II A 11, IIA12, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, or XV; compound of Formula F, IF, I”, II”, 1-1, 1-F, 1-1”, I-G”, 1-3, 1-4, II- 1, XVI, XVII, XVIII, or XIX), or a pharmaceutically acceptable salt or solvate thereof.
- a compound described herein e.g., compound of Formula I, I
- a method of modulating activity of a Ras comprising contacting a Ras protein with an effective amount of a compound described herein (e.g., compound of Formula I, IA1, IA2, 1 A3, IA4, IA5, IA6, IA7, IA8, IA9, IA10, IA11, IA12, II, IIA1, IIA2, IIA3, IIA4, IIA5, IIA6, IIA7, IIA8, IIA9, IIA10, IIA11, IIA12, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, or XV; compound of Formula F, IF, I”, II”, 1-1, 1-r, 1-1”, I-G”, 1-3, 1-4, II-l, XVI, XVII, XVIII, or XIX), or a pharmaceutically acceptable salt or solvate thereof
- a compound described herein e.g., compound of Formula I, IA1,
- the subject method comprises administering an additional agent or therapy.
- a method of inhibiting cell growth comprising administering an effective amount of a compound described herein (e.g., compound of Formula I, IA1, IA2, IA3, IA4, IA5, IA6, IA7, IA8, IA9, IA10, IA11, IA12, II, IIA1, IIA2, IIA3, IIA4, IIA5, IIA6, IIA7, IIA8, IIA9, IIA10, IIA11, IIA12, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, or XV; compound of Formula F, IF, I”, II”, 1-1, 1-G, 1-1”, I-F”, 1-3, 1-4, II- 1, XVI, XVII, XVIII, or XIX), or a pharmaceutically acceptable salt or solvate thereof, to a cell expressing a Ras (e.g., K- Ras) protein,
- a Ras e.g
- a Ras (e.g., K-Ras) protein bound by a compound described herein e.g., compound of Formula I, IA1, IA2, IA3, IA4, IA5, IA6, IA7, IA8, IA9, IA10, IA11, IA12, II, IIA1, IIA2, IIA3, IIA4, IIA5, IIA6, IIA7, IIA8, IIA9, IIA10, IIA11, IIA12, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, or XV; compound of Formula F, IF, I”, II”, 1-1, 1-G, 1-1”, I-G”, 1-3, 1-4, II- 1, XVI, XVII, XVIII, or XIX), or a pharmaceutically acceptable salt or solvate thereof, wherein activity of said Ras (e.g., K-Ras) protein is
- Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
- Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques can be performed e.g., using kits of manufacturer's specifications or as commonly accomplished in the art or as described herein.
- Ci-C x includes C1-C2, C1-C3 . . . Ci-C x .
- Ci-C x refers to the number of carbon atoms that make up the moiety to which it designates (excluding optional substituents).
- an “alkyl” group refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation.
- the “alkyl” group may have 1 to 18, 1 to 12, 1 to 10, 1 to 8, or 1 to 6 carbon atoms (whenever it appears herein, a numerical range such as “1 to 6” refers to each integer in the given range; e.g. , “ 1 to 6 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated).
- the alkyl group of the compounds described herein may be designated as “Ci-Cealkyl” or similar designations.
- “Ci-Cealkyl” indicates that there are one to six carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, and hexyl.
- Alkyl groups can be substituted or unsubstituted.
- an alkyl group can be a monoradical or a diradical (i.e., an alkylene group).
- alkoxy refers to a “-O-alkyl” group, where alkyl is as defined herein.
- alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond.
- an alkenyl groups may have 2 to 6 carbons.
- Alkenyl groups can be substituted or unsubstituted. Depending on the structure, an alkenyl group can be a monoradical or a diradical (i.e., an alkenylene group).
- alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond.
- alkynyl group include -CoCH, -CoCCH 3 , -CoCCH 2 CH 3 and -CoCCH 2 CH 2 CH 3 .
- an alkynyl group can have 2 to 6 carbons.
- Alkynyl groups can be substituted or unsubstituted.
- an alkynyl group can be a monoradical or a diradical (i.e., an alkynylene group).
- Amino refers to a -NH 2 group.
- “Dialkylamino” refers to a -N(alkyl) 2 group, where alkyl is as defined herein.
- aromatic refers to a planar ring having a delocalized p-electron system containing 4n+2 p electrons, where n is an integer. Aromatic rings can be formed from five, six, seven, eight, nine, or more than nine atoms. Aromatics can be optionally substituted.
- aromatic includes both aryl groups (e.g., phenyl, naphthalenyl) and heteroaryl groups (e.g., pyridinyl, quinolinyl).
- aryl refers to a monocyclic aromatic ring wherein each of the atoms forming the ring is a carbon atom (e.g., phenyl) or a polycyclic ring system (e.g., bicyclic or tricyclic) wherein 1) at least one ring is carbocyclic and aromatic, 2) a bond to the remainder of the compound is directly bonded to a carbocyclic aromatic ring of the aryl ring system, and 3) the carbocyclic aromatic ring of the aryl ring system of 2) is not directly bonded (e.g., fused) to a heteroaryl ring in the polycyclic ring system.
- a carbon atom e.g., phenyl
- a polycyclic ring system e.g., bicyclic or tricyclic
- Aryl rings can be formed by five, six, seven, eight, nine, or more than nine carbon atoms.
- Aryl groups can be optionally substituted.
- Examples of aryl groups include, but are not limited to phenyl, and naphthalenyl.
- an aryl group can be a monoradical or a diradical (i.e., an arylene group).
- the aryl radical is a monocyclic, bicyclic, or tricyclic ring system.
- an aryl is a monocyclic ring.
- an aryl is a fused ring polycyclic system.
- an aryl is a bridged ring polycyclic system.
- the aryl is a “fused ring aryl” wherein the aryl ring is fused with a cycloalkyl or a heterocycloalkyl ring.
- Carboxy refers to -CO2H.
- carboxy moieties may be replaced with a “carboxylic acid bioisostere”, which refers to a functional group or moiety that exhibits similar physical and/or chemical properties as a carboxylic acid moiety.
- a carboxylic acid bioisostere has similar biological properties to that of a carboxylic acid group.
- a compound with a carboxylic acid moiety can have the carboxylic acid moiety exchanged with a carboxylic acid bioisostere and have similar physical and/or biological properties when compared to the carboxylic acid-containing compound.
- a carboxylic acid bioisostere would ionize at physiological pH to roughly the same extent as a carboxylic acid group.
- bioisosteres of a carboxylic acid include, but are not limited to, and the like.
- cycloalkyl refers to a monocyclic carbocyclic saturated or partially unsaturated non-aromatic ring or a polycyclic carbocyclic (i.e., does not include heteroatom(s)) ring system (e.g., bicyclic or tricyclic) wherein 1) at least one ring is carbocyclic saturated or partially unsaturated and non-aromatic, 2) a bond to the remainder of the compound is directly bonded to a carbocyclic saturated or partially unsaturated non-aromatic ring of the ring system, and 3) the carbocyclic saturated or partially unsaturated non-aromatic ring of the ring system of 2) is not directly bonded (e.g., fused or spirocyclic) to a heterocycloalkyl ring in the polycyclic ring system.
- heteroatom(s) ring system
- Cycloalkyls may be saturated or partially unsaturated.
- a cycloalkyl ring is a spirocyclic cycloalkyl ring.
- a cycloalkyl is a monocyclic ring.
- a cycloalkyl is a fused ring polycyclic system.
- a cycloalkyl is a bridged ring polycyclic system.
- a cycloalkyl is a spirocyclic polycyclic ring system.
- cycloalkyl groups include groups having from 3 to 10 ring atoms.
- a cycloalkyl group can be a monoradical or a diradical (i.e., a cycloalkylene group).
- heteroaryl or, alternatively, “heteroaromatic” refers to an monocyclic aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur; or a polycyclic ring system (e.g., bicyclic or tricyclic) wherein 1) at least one ring is aromatic and includes one or more heteroatoms selected from nitrogen, oxygen and sulfur and 2) a bond to the remainder of the compound is directly bonded to an aromatic ring including one or more heteroatoms selected from nitrogen, oxygen and sulfur or an aromatic ring directly bonded (e.g., fused) to an aromatic ring including one or more heteroatoms selected from nitrogen, oxygen and sulfur, of the aryl ring system.
- the heteroaryl radical may be a monocyclic, bicyclic, or tricyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated (i.e., aromatic) and includes a heteroatom.
- a heteroaryl is a monocyclic ring.
- a heteroaryl is a fused ring polycyclic system.
- a heteroaryl is a bridged ring polycyclic system.
- Y-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.
- a heteroaryl group can be a monoradical or a diradical (i.e., a heteroarylene group).
- a “heterocycloalkyl” group or “heteroalicyclic” group refers to a cycloalkyl group, wherein at least one skeletal ring atom of a saturated or partially unsaturated non-aromatic ring is a heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur.
- a heterocycloalkyl refers to a monocyclic saturated or partially unsaturated nonaromatic ring including one or more heteroatoms or a polycyclic ring system (e.g., bicyclic or tricyclic) wherein 1) at least one ring is saturated or partially unsaturated, non-aromatic, and includes one or more heteroatoms and 2) a bond to the remainder of the compound is directly bonded to a ring of the ring system that is a saturated or partially unsaturated and non-aromatic ring that includes one or more heteroatoms or a non-aromatic ring directly bonded (e.g., fused) to a saturated or partially unsaturated and non-aromatic ring that includes one or more heteroatoms of the ring system.
- a polycyclic ring system e.g., bicyclic or tricyclic
- Heterocycloalkyls may be saturated or partially unsaturated.
- the term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides.
- a heterocycloalkyl ring is a spirocyclic heterocycloalkyl ring.
- a heterocycloalkyl is a monocyclic ring.
- a heterocycloalkyl is a fused ring polycyclic system.
- a heterocycloalkyl is a bridged ring polycyclic system.
- a heterocycloalkyl is a spirocyclic polycyclic ring system. Unless otherwise noted, heterocycloalkyls have from 2 to 13 carbons in the ring or ring system. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring).
- a heterocycloalkyl group can be a monoradical or a diradical (i.e., a heterocycloalkylene group).
- halo or, alternatively, “halogen” means fluoro, chloro, bromo and iodo.
- haloalkyl refers to an alkyl group that is substituted with one or more halogens.
- the halogens may the same or they may be different.
- Non-limiting examples of haloalkyls include -CH 2 C1, -CF , -CHF 2 , - CH 2 CF 3 , -CF 2 CF 3 , and the like.
- fluoroalkyl and “fluoroalkoxy” include alkyl and alkoxy groups, respectively, that are substituted with one or more fluorine atoms.
- fluoroalkyls include -CF 3 , -CHF 2 , -CH 2 F, - CH 2 CF 3 , -CF 2 CF 3 , -CF 2 CF 2 CF 3 , -CF(CH 3 ) 3 , and the like.
- Non-limiting examples of fluoroalkoxy groups include - OCF 3 , -OCHF 2 , -OCH 2 F, -OCH 2 CF 3 , -OCF 2 CF 3 , -OCF 2 CF 2 CF 3 , -OCF(CH 3 ) 2 , and the like.
- heteroalky lene linker refers to a divalent alkyl radical where one or more skeletal chain atoms is selected from an atom other than carbon, e.g. , oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof.
- the heteroatom(s) may be placed at any interior position of the heteroalkyl group.
- the heteroatom(s) may be placed at one or both terminal positions of the heteroalkylene linker (i.e., position(s) directly bonded to portion(s) of the molecule other than the heteroalkylene linker).
- Examples include, but are not limited to, -CH 2 -0-, -CH 2 -CH 2 -0-, -CH 2 -NH-, -CH 2 -CH 2 -NH-, -CH 2 -N(CH 3 )-, -CH 2 -CH 2 -N(CH 3 )-, -CH 2 -S-, -CH 2 - CH 2 -S-, -CH 2 -CH 2 -S(0)-, -CH 2 -CH 2 -S(0) 2 -, -CH 2 -S(0)-, -CH 2 -S(0)-, -CH 2 -S(0) 2 -, -CH 2 -CH 2 -CH 2 -S(0)-, -CH 2 -CH 2 -CH 2 -S(0)-, -CH 2 -CH 2 -CH 2 -S(0)-, -CH 2 -CH 2 -CH 2 -S(0)-, -CH 2 -CH 2 -CH 2 -S
- Examples include, but are not limited to, -0-CH 2 -, -0-CH 2 -CH 2 -, -NH-CH 2 -, -NH-CH 2 - CH 2 -, -N(CH 3 )-CH 2 -, -N(CH 3 )-CH 2 -CH 2 -, -S-CH 2 -, -S-CH 2 -CH 2 -, -S(0)-CH 2 -CH 2 -, -S(0) 2 -CH 2 -CH 2 -, -S(0) 2 -CH 2 -, -S(0)-CH 2 -, -S(0) 2 -CH 2 -, -S(0)-CH 2 -CH 2 -, -S(0)-CH 2 -CH 2 -, -S(0)-CH 2 -CH 2 -CH 2 -, -S(0) 2 -CH 2 -CH 2 -, -S(0) 2 -CH 2 -CH 2 -, -S(0) 2 -
- heteroatoms may be consecutive, such as, by way of example, -CH 2 -NH-0- and -0-Si(CH 3 ) 2 -.
- examples include, but are not limited to, -P(0)(CH 3 )-CH 2 -, -P(0)(CH 3 )-CH 2 -CH 2 -, -P(0)(CH 3 )-CH 2 -CH 2 -,-CH 2 -P(0)(CH 3 )-, -CH 2 -CH 2 -P(0)(CH 3 )-, and -CH 2 -CH 2 -CH 2 -P(0)(CH 3 )-.
- heteroatoms may be consecutive, such as, by way of example, -CH 2 -NH-0- and -0-Si(CH 3 ) 2 -.
- A“heteroalkylene linker” may have from 2 to 4 main chain atoms unless specified otherwise.
- heteroalkyl refers to an alkyl radical where one or more skeletal chain atoms is selected from an atom other than carbon, e.g. , oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof.
- the heteroatom(s) may be placed at any interior position of the heteroalkyl group.
- heteroalkyl may have from 1 to 6 carbon atoms.
- bond refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.
- moiety refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.
- substituent “R” appearing by itself and without a number designation refers to a substituent selected from among from alkyl, haloalkyl, heteroalkyl, alkenyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heterocycloalkyl.
- “Pharmaceutically acceptable salt” includes both acid and base addition salts.
- a pharmaceutically acceptable salt of any one of the compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
- Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc.
- acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
- Acid addition salts of basic compounds are, in some embodiments, prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
- “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Pharmaceutically acceptable base addition salts are, in some embodiments, formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, Y, ⁇ -dibcnzylcthylcncdiaminc.
- polypeptide refers to polymers of amino acids of any length.
- the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
- the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
- amino acid refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
- polynucleotide refers to a polymeric form of nucleotides of any length, either deoxy ribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown.
- polynucleotides coding or noncoding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
- loci locus defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polyn
- a polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs, such as peptide nucleic acid (PNA), Morpholino and locked nucleic acid (LNA), glycol nucleic acid (GNA), threose nucleic acid (TNA), 2’-fluoro, 2’-OMe, and phosphorothiolated DNA. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component or other conjugation target.
- modified nucleotides such as methylated nucleotides and nucleotide analogs, such as peptide nucleic acid (PNA), Morpholino and locked nucleic acid (LNA), glycol nucle
- expression refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins.
- Transcripts and encoded polypeptides may be collectively referred to as “gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.
- the terms “subject,” “individual,” and “patient” are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells, and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
- therapeutic agent refers to a molecule or compound that confers some beneficial effect upon administration to a subject.
- the beneficial effect includes enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition.
- treatment or “treating,” or “palliating” or “ameliorating” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit.
- therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment.
- the compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.
- prophylactic benefit includes reducing the incidence and/or worsening of one or more diseases, conditions, or symptoms under treatment (e.g. as between treated and untreated populations, or between treated and untreated states of a subject).
- the term “effective amount” or “therapeutically effective amount” refers to the amount of an agent that is sufficient to effect beneficial or desired results.
- the therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- An effective amount of an active agent may be administered in a single dose or in multiple doses.
- a component may be described herein as having at least an effective amount, or at least an amount effective, such as that associated with a particular goal or purpose, such as any described herein.
- the term “effective amount” also applies to a dose that will provide an image for detection by an appropriate imaging method.
- the specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
- in vivo refers to an event that takes place in a subject’s body.
- ex vivo refers to an event that first takes place outside of the subject’s body for a subsequent in vivo application into a subject’s body.
- ex vivo preparation may involve preparation of cells outside of a subject’s body for the purpose of introduction of the prepared cells into the same or a different subject’s body.
- in vitro refers to an event that takes place outside of a subject’s body.
- an in vitro assay encompasses any assay ran outside of a subject’s body.
- In vitro assays encompass cell-based assays in which cells alive or dead are employed.
- In vitro assays also encompass a cell-free assay in which no intact cells are employed.
- Ras refers to a protein in the Rat sarcoma (Ras) superfamily of small GTPases, such as in the Ras subfamily.
- the Ras superfamily includes, but is not limited to, the Ras subfamily, Rho subfamily, Rab subfamily, Rap subfamily, Arf subfamily, Ran subfamily, Rheb subfamily, RGK subfamily, Rit subfamily, Miro subfamily, and Unclassified subfamily.
- a Ras protein is selected from the group consisting of KRAS (also used interchangeably herein as K-Ras, K-ras, Kras), HRAS (or H-Ras), NRAS (or N-Ras), MRAS (or M-Ras), ERAS (or E-Ras), RRAS2 (or R-Ras2), RALA (or RalA), RALB (or RalB), RIT1, and any combination thereof, such as from KRAS, HRAS, NRAS, RALA, RALB, and any combination thereof.
- KRAS also used interchangeably herein as K-Ras, K-ras, Kras
- HRAS or H-Ras
- NRAS or N-Ras
- MRAS or M-Ras
- ERAS or E-Ras
- RRAS2 or R-Ras2
- RALA or RalA
- RALB or RalB
- a mutant Ras refers to a Ras protein with one or more amino acid mutations, such as with respect to a common reference sequence such as a wild-type (WT) sequence.
- a mutant Ras is selected from a mutant KRAS, mutant HRAS, mutant NRAS, mutant MRAS, mutant ERAS, mutant RRAS2, mutant RALA, mutant RALB, mutant RIT1, and any combination thereof, such as from a mutant KRAS, mutant HRAS, mutant NRAS, mutant RALA, mutant RALB, and any combination thereof.
- a mutation can be an introduced mutation, a naturally occurring mutation, or a non-naturally occurring mutation.
- a mutation can be a substitution (e.g., a substituted amino acid), insertion (e.g., addition of one or more amino acids), or deletion (e.g., removal of one or more amino acids).
- two or more mutations can be consecutive, non-consecutive, or a combination thereof.
- a mutation can be present at any position of Ras.
- a mutation can be present at position 12, 13, 62, 92, 95, or any combination thereof of Ras relative to SEQ ID No. 1 when optimally aligned.
- a mutant Ras may comprise about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more than 50 mutations. In some embodiments, a mutant Ras may comprise up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 mutations.
- the mutant Ras is about or up to about 500, 400, 300, 250, 240, 233, 230, 220, 219, 210, 208, 206, 204, 200, 195, 190, 189, 188, 187, 186, 185, 180, 175, 174, 173, 172, 171, 170, 169, 168, 167, 166, 165, 160, 155, 150, 125, 100, 90, 80, 70, 60, 50, or fewer than 50 amino acids in length.
- an amino acid of a mutation is a proteinogenic, natural, standard, non-standard, non- canonical, essential, non-essential, or non-natural amino acid.
- an amino acid of a mutation has a positively charged side chain, a negatively charged side chain, a polar uncharged side chain, a non-polar side chain, a hydrophobic side chain, a hydrophilic side chain, an aliphatic side chain, an aromatic side chain, a cyclic side chain, an acyclic side chain, a basic side chain, or an acidic side chain.
- a mutation comprises a reactive moiety.
- a substituted amino acid comprises a reactive moiety.
- a mutant Ras can be lurther modified, such as by conjugation with a detectable label.
- a mutant Ras is a full-length or truncated polypeptide.
- a mutant Ras can be a truncated polypeptide comprising residues 1-169 or residues 11-183 (e.g., residues 11-183 of a mutant RALA or mutant RALB).
- [00144] indicates the location of attachment (e.g., location of a bond to another atom) of the depicted chemical formula or atom to a substituent, a further component of a molecule, or an atom.
- a substituent e.g., location of a bond to another atom
- a further component of a molecule e.g., a further component of a molecule
- an atom e.g., a further component of a molecule, or an atom.
- a selected residue in a protein corresponds to Cysl2 of a human Ras (e.g., human K-Ras) protein when the selected residue occupies the same essential spatial or other structural position as Cysl2 in the human Ras (e.g., human K-Ras) protein.
- a selected protein is aligned for maximum homology with the human Ras (e.g., human K-Ras) protein
- the position in the aligned selected protein aligning with Cysl2 is said to correspond to Cysl2.
- a three dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the human K-Ras protein and the overall structures compared.
- an amino acid that occupies the same essential position as Cysl2 in the structural model is said to correspond to the Cysl2 residue.
- a selected residue in a protein corresponds to Cysl3 of a human Ras (e.g., human K-Rasa) protein when the selected residue occupies the same essential spatial or other structural position as Cysl3 in a human Ras (e.g., human K-Ras) protein, similar to the example of Cysl2 above.
- a human Ras e.g., human K-Rasa
- a C3-iocycloalkyl is a 3 membered cycloalkyl. In embodiments, a C3-iocycloalkyl is a 4 membered cycloalkyl. In embodiments, a C3-iocycloalkyl is a 5 membered cycloalkyl. In embodiments, a C3- l ocycloalkyl is a 6 membered cycloalkyl. In embodiments, a C3-iocycloalkyl is a 7 membered cycloalkyl. In embodiments, a C3-iocycloalkyl is a 8 membered cycloalkyl.
- a C3-iocycloalkyl is a 9 membered cycloalkyl. In embodiments, a C3-iocycloalkyl is a 10 membered cycloalkyl. In embodiments, a C3-iocycloalkyl is a 3-10 membered cycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 3 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 4 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 5 membered heterocycloalkyl.
- a C2-9heterocycloalkyl is a 6 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 7 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 8 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 9 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 10 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a ll membered heterocycloalkyl.
- a C2-9heterocycloalkyl is a 12 membered heterocycloalkyl. In embodiments, a C2-9heterocycloalkyl is a 3-12 membered heterocycloalkyl. In embodiments, a C2- li heterocycloalkyl is a 3 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 4 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 5 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 6 membered heterocycloalkyl.
- a C2-iiheterocycloalkyl is a 7 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 8 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 9 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 10 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 11 membered heterocycloalkyl. In embodiments, a C2-iiheterocycloalkyl is a 12 membered heterocycloalkyl.
- a C2-iiheterocycloalkyl is a 3-12 membered heterocycloalkyl.
- a Ci-nheterocycloalkyl is a 3 membered heterocycloalkyl.
- a Ci-nheterocycloalkyl is a 4 membered heterocycloalkyl.
- a Ci-nheterocycloalkyl is a 5 membered heterocycloalkyl.
- a Ci-nheterocycloalkyl is a 6 membered heterocycloalkyl.
- a Ci-nheterocycloalkyl is a 7 membered heterocycloalkyl.
- a Ci-nheterocycloalkyl is a 8 membered heterocycloalkyl. In embodiments, a Ci-nheterocycloalkyl is a 9 membered heterocycloalkyl. In embodiments, a Ci-nheterocycloalkyl is a 10 membered heterocycloalkyl. In embodiments, a Ci-nheterocycloalkyl is a 11 membered heterocycloalkyl. In embodiments, a Ci-nheterocycloalkyl is a 12 membered heterocycloalkyl. In embodiments, a Ci-nheterocycloalkyl is a 3-12 membered heterocycloalkyl.
- a C6-i2aryl is a 6 membered aryl. In embodiments, a C6-i2aryl is a 7 membered aryl. In embodiments, a C6-i2aryl is a 8 membered aryl. In embodiments, a C6-i2aryl is a 9 membered aryl. In embodiments, a C6-i2aryl is a 10 membered aryl. In embodiments, a C6-i2aryl is a 11 membered aryl. In embodiments, a C6-i2aryl is a 12 membered aryl.
- a C6-i2aryl is a 6-12 membered aryl.
- a Ci-nheteroaryl is a 5 membered heterocycloalkyl.
- a Ci-nheteroaryl is a 6 membered heterocycloalkyl.
- a Ci- nheteroaryl is a 7 membered heterocycloalkyl.
- a Ci-nheteroaryl is a 8 membered heterocycloalkyl.
- a Ci-nheteroaryl is a 9 membered heterocycloalkyl.
- a Ci-nheteroaryl is a 10 membered heterocycloalkyl. In embodiments, a Ci-nheteroaryl is a 11 membered heterocycloalkyl. In embodiments, a Ci-nheteroaryl is a 12 membered heterocycloalkyl. In embodiments, a Ci-nheteroaryl is a 5-12 membered heterocycloalkyl. In embodiments, a C3-6cycloalkyl is a 3 membered cycloalkyl. In embodiments, a C3- 6 cycloalkyl is a 4 membered cycloalkyl.
- a C3-6cycloalkyl is a 5 membered cycloalkyl. In embodiments, a C3-6cycloalkyl is a 6 membered cycloalkyl. In embodiments, a C 6 -ioaryl is a 6 membered aryl. In embodiments, a C 6 -ioaryl is a 7 membered aryl. In embodiments, a C 6 -ioaryl is a 8 membered aryl. In embodiments, a C 6 -ioaryl is a 9 membered aryl. In embodiments, a C 6 -ioaryl is a 10 membered aryl.
- a Ci- gheteroaryl is a 5 membered heterocycloalkyl. In embodiments, a Ci-gheteroaryl is a 6 membered heterocycloalkyl. In embodiments, a Ci-gheteroaryl is a 7 membered heterocycloalkyl. In embodiments, a Ci-gheteroaryl is a 8 membered heterocycloalkyl. In embodiments, a Ci-gheteroaryl is a 9 membered heterocycloalkyl. In embodiments, a Ci-gheteroaryl is a 10 membered heterocycloalkyl.
- a Ci-gheteroaryl is a 11 membered heterocycloalkyl.
- a Cj-dictcroaryl is a 12 membered heterocycloalkyl.
- a Ci- yhctcroan l is a 5-12 membered heterocycloalkyl.
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 17 ) and J is C(R 16 ), or V is C(R 17 ) and J is N, or J is C(R 17 ) and V is C(R 16 ), or J is C(R 17 ) and V is N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- R 7 is a 3-12 membered nitrogen containing heterocycloalkyl or 5-12 membered nitrogen containing heteroaryl, wherein the 3-12 membered nitrogen containing heterocycloalkyl or 5-12 membered nitrogen containing heteroaryl are optionally substituted with one or more R 1 , one or more R 4 , or one or more R 6 ; wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i 2 cycloalkyl, Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl, wherein the C3-i 2 cycloalkyl, Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl are optionally substituted with one, two, or three R 20a ; each R 1 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, Ci-Cealkyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C 2 - dictcrocycloalkyl. C 6 -ioaryl, Ci-dictcroaiyl.
- R 17 is -LkR 19 ;
- L 1 is selected from a bond, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ), and C(R
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), - C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , - S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )
- R lc is selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, CV,- ioaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201
- R 19 is selected from a C3-i2cycloalkyl, C2-nheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl, wherein the C3- ncycloalkyl, C2-iiheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3- 6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , - 0C(0)N(R 12 )(R
- R 16 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci- ⁇ ) hctcroan l.
- R 12a is selected from Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, G- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CEC-G-ioaryl, -CH2-Ci-9heteroaryl, and Ci- gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, G- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CEC-G-ioaryl, -CH2-Ci-9heteroaryl, and Ci- gheteroary
- R 12b is selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, G- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CEh-Ci-gheteroaryl, and Ci- gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C 2 - gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CEh-Ci-ghe
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci ⁇ alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S
- Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 20f ; each R 20a , R 20b , R 20c , R 20d , R 20e , R 20f , R 20g , and R 201 are each independently selected from halogen, -CN, Ci- 6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl, C2-9heterocycloalkyl, -CH2-C2- gheterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH2-Ci-9he
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 17 ) and J is C(R 16 ), or V is C(R 17 ) and J is N, or J is C(R 17 ) and V is C(R 16 ), or J is C(R 17 ) and V is N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- R 7 is a 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl, wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i2cycloalkyl, Ci-nhetero
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, G-Galkyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2- gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0) 2 R
- R 17 is -G-R 19 ;
- L 1 is selected from a bond, G-Galkyl, C2-C6alkenyl, G-Galkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ), and C(R l
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-dictcroarvl.
- gheterocycloalkyl, C 6 -ioaryl, and Ci-dictcroarvl are optionally substituted with one, two, or three R 201 ; or R lf and R lg are joined to form a 4-7 membered heterocycloalkyl ring or a 4-7 membered cycloalkyl ring, wherein the 4-7 membered heterocycloalkyl ring or 4-7 membered cycloalkyl ring are optionally substituted with one, two, or three R 201 ;
- R lc is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, CV,. ioaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201
- R 19 is selected from a C3-i 2 cycloalkyl, C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl, wherein the C3- i 2 cycloalkyl.
- C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3- 6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , - 0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)
- R 16 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0)
- R 12a is selected from Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -C(R 12c ) 2 -C3-iocycloalkyl, C 2.
- R 12b is selected from hydrogen, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocyeloalkyl, C 2 - gheterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocyeloalkyl, C6-ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci- 9 heteroaryl, and Ci-gheteroaryl, wherein Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocyeloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2
- R 12c is independently selected from hydrogen and R 20k ;
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 ,
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -C 1 - gheteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -io
- Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 20f ; each R 20a , R 20b , R 20c , R 20d , R 20e , R 20f , R 20g , R 201 , and R 20k are each independently selected from halogen, oxo, - CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2 - gheterocycloalkyl, C 6 -ioaryl, -CH 2
- X is C(R 3 ). In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, X is N.
- V is C(R 16 ) and J is C(R 17 ). In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, V is N and J is C(R 17 ). In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, J is N and V is C(R 17 ). In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, J is C(R 16 ) and V is C(R 17 ). In further embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is C(O). In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is S(O). In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, W is S(0) 2 .
- the compound has the structure: Formula (IA6), 12).
- the compound has the structure: ), , 2).
- L 7 is a bond. In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, L 7 is -NH-.
- L 7 is a bond. In embodiments, L 7 is -0-. In embodiments, L 7 is -N(R 14 )-. In embodiments, L 7 is -C(O)-. In embodiments, L 7 is -N(R 14 )C(0)-. In embodiments, L 7 is -C(0)N(R 14 )-. In embodiments, L 7 is -S-. In embodiments, L 7 is -S(0) 2 -. In embodiments, L 7 is -S(O)-. In embodiments, L 7 is - S(0) 2 N(R 14 )-. In embodiments, L 7 is -S(0)N(R 14 )-.
- L 7 is -N(R 14 )S(0)-. In embodiments, L 7 is - N(R 14 )S(0) 2 -. In embodiments, L 7 is Ci-Cealkyl. In embodiments, L 7 is C2-C6alkenyl. In embodiments, L 7 is C2- Cealkynyl. In embodiments, L 7 is 2 to 4 membered heteroalkylene linker. In embodiments, L 7 is Ci-Cealkyl optionally substituted with one, two, or three R 20a . In embodiments, L 7 is C2-C6alkenyl optionally substituted with one, two, or three R 20a .
- L 7 is C2-Cealkynyl optionally substituted with one, two, or three R 20a . In embodiments, L 7 is 2 to 4 membered heteroalkylene linker optionally substituted with one, two, or three R 20a . In embodiments, L 7 is -N(H)-. In embodiments, L 7 is -N(H)C(0)-. In embodiments, L 7 is -C(0)N(H)-. In embodiments, L 7 is -S(0) 2 N(H)-. In embodiments, L 7 is -S(0)N(H)-. In embodiments, L 7 is -N(H)S(0)-. In embodiments, L 7 is -N(H)S(0) 2 -.
- R 7 is a 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl, wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the a 4- 12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent
- R 7 is a 3-12 membered nitrogen containing heterocycloalkyl, wherein the 3-12 membered nitrogen containing heterocycloalkyl is optionally substituted with one or more R 1 , one or more R 4 , or one or more R 6 ; and wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i2cycloalkyl, Ci-nheterocycloalkyl, C6-i2aryl, or Ci-nheteroaryl, wherein the C3-i2cycloalkyl, Ci- li heterocycloalkyl, C6-i2aryl, or Ci-nheteroaryl are optionally substituted with one, two, or three R 20a .
- R 7 is a 3-12 membered nitrogen containing heterocycloalkyl, wherein the 3-12 membered nitrogen containing heterocycloalkyl is optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; and wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i2cycloalkyl, Ci-nheterocycloalkyl, G,.
- naryl, or Ci-nheteroaryl wherein the C3-i2cycloalkyl, Ci-nheterocycloalkyl, C6-i2aryl, or G-iiheteroaryl are optionally substituted with one, two, or three R 20a .
- R 7 is a 3-12 membered cycloalkyl. In embodiments, R 7 is a 5-12 membered cycloalkyl.
- R 7 is 3-12 membered heterocycloalkyl. In embodiments, R 7 is 6-12 membered aryl. In embodiments, R 7 is 7-12 membered aryl. In embodiments, R 7 is 5-12 membered heteroaryl.
- R 7 is a 3-12 membered cycloalkyl comprising one or more ring nitrogen atoms. In embodiments, R 7 is a 5-12 membered cycloalkyl comprising one or more ring nitrogen atoms. In embodiments, R 7 is 3-12 membered heterocycloalkyl comprising one or more ring nitrogen atoms. In embodiments, R 7 is 6-12 membered aryl comprising one or more ring nitrogen atoms. In embodiments, R 7 is 7-12 membered aryl comprising one or more ring nitrogen atoms. In embodiments, R 7 is 5-12 membered heteroaryl comprising one or more ring nitrogen atoms.
- R 7 is a 3-12 membered cycloalkyl comprising one or more ring oxygen atoms. In embodiments, R 7 is a 5-12 membered cycloalkyl comprising one or more ring oxygen atoms. In embodiments, R 7 is 3-12 membered heterocycloalkyl comprising one or more ring oxygen atoms. In embodiments, R 7 is 6-12 membered aryl comprising one or more ring oxygen atoms. In embodiments, R 7 is 7-12 membered aryl comprising one or more ring oxygen atoms. In embodiments, R 7 is 5-12 membered heteroaryl comprising one or more ring oxygen atoms.
- R 7 is a 3-12 membered cycloalkyl optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is a 5-12 membered cycloalkyl optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 3-12 membered heterocycloalkyl optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 6-12 membered aryl optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 7-12 membered aryl optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 5-12 membered heteroaryl optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is a 3-12 membered cycloalkyl comprising one or more ring nitrogen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is a 5-12 membered cycloalkyl comprising one or more ring nitrogen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 3-12 membered heterocycloalkyl comprising one or more ring nitrogen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 6-12 membered aryl comprising one or more ring nitrogen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 7-12 membered aryl comprising one or more ring nitrogen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 5-12 membered heteroaryl comprising one or more ring nitrogen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is a 3-12 membered cycloalkyl comprising one or more ring oxygen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is a 5-12 membered cycloalkyl comprising one or more ring oxygen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 3-12 membered heterocycloalkyl comprising one or more ring oxygen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 6-12 membered aryl comprising one or more ring oxygen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 7-12 membered aryl comprising one or more ring oxygen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is 5-12 membered heteroaryl comprising one or more ring oxygen atoms optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 .
- R 7 is a C3cycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cicycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cecycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a C7cycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a Ciocycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a monocyclic Cicycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cecycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic C7cycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Ciocycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cecycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C7cycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cecycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Ciocycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cecycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C7cycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Ciocycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cecycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic C7cycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Ciocycloalkyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cicycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cecycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a C7cycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a Ciocycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cicycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cecycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic C7cycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a monocyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a monocyclic Ciocycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cecycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C7cycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Ciocycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cecycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C7cycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Ciocycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cecycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic C7cycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Ciocycloalkyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a fused bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a fused bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cecycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic C7cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Ciocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a fused bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cecycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic C7cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cscycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Cycvcloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic Ciocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered cycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered cycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 3 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 4 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 3 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 4 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 3 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 4 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 3 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 4 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered heterocycloalkyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 3 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 4 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 3 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 4 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 3 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 4 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 3 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 4 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 5 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered heterocycloalkyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cearyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a C-aiyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cearyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cioaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cearyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic C-aiy 1 optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Csaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cearyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cioaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cearyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C-aiyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Co aryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cioaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cearyl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C-arvl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Coaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cioaryl optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a C-arvl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cioaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cearyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C-arvl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic arvl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cioaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cearyl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C-arvl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic arvl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cioaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cearyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a C-arvl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Co aryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cioaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cearyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic C-aiy 1 optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Csaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Gaiyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic Cioaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a fused bicyclic Csaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a fused bicyclic C-arv 1 optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a fused bicyclic Csaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Gaiyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cioaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cearyl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Caryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Caryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cioaryl optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Caryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cioaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cearyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Caryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Caryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cioaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cearyl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Caryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Caryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cioaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a C-arvl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cyarvl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a Cioaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Giaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C-arvl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Coaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cioaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cearyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C-arvl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cearyl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cioaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a C-arvl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Csaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a Cioaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cearyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic C-arvl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cearyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic Cioaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cearyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic C-aiyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Csaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cyaiyl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic Cioaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 12 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered aryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 12 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered aryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 12 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered aryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 10 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 11 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 12 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered aryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 5 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 11 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 12 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 11 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 12 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 11 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 12 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 5 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heteroaryl including at least one nitrogen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 5 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 6 and optionally substituted with one or more R 4 .
- R 7 is a 5 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . [00243] In embodiments, R 7 is a monocyclic 5 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 . In embodiments, R 7 is a monocyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a monocyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a fused bicyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a bridged bicyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 6 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 7 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 8 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 9 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 7 is a spirocyclic bicyclic 10 membered heteroaryl including at least one oxygen atom and optionally substituted with one R 1 and optionally substituted with one or more R 4 .
- R 4 is independently halogen. In embodiments, R 4 is independently R 4 is independently oxo. In embodiments, R 4 is independently -CN. In embodiments, R 4 is independently Ci- 6 alkyl. In embodiments,
- R 4 is independently C2-6alkenyl. In embodiments, R 4 is independently C2-6alkynyl. In embodiments, R 4 is independently Ci- 6 haloalkyl. In embodiments, R 4 is independently C3-i2cycloalkyl. In embodiments, R 4 is independently -CH2-C3-i2cycloalkyl. In embodiments, R 4 is independently Ci-nheterocycloalkyl. In embodiments, R 4 is independently -CtC-Ci-nheterocycloalkyl. In embodiments, R 4 is independently C6-i2aryl. In embodiments,
- R 4 is independently -CH 2 -C6-i2aryl. In embodiments, R 4 is independently -CtC-Ci-nheteroaryl. In embodiments, R 4 is independently Ci-nheteroaryl. In embodiments, R 4 is independently -OR 12 . In embodiments, R 4 is independently -SR 12 . In embodiments, R 4 is independently -N(R 12 )(R 13 ). In embodiments, R 4 is independently -C(0)0R 12 . In embodiments, R 4 is independently -0C(0)N(R 12 )(R 13 ). In embodiments, R 4 is independently - N(R 14 )C(0)N(R 12 )(R 13 ).
- R 4 is independently -N(R 14 )C(0)0R 15 . In embodiments, R 4 is independently -N(R 14 )S(0) 2 R 15 . In embodiments, R 4 is independently -C(0)R 15 . In embodiments, R 4 is independently -S(0)R 15 . In embodiments, R 4 is independently -0C(0)R 15 . In embodiments, R 4 is independently - C(0)N(R 12 )(R 13 ). In embodiments, R 4 is independently -C(0)C(0)N(R 12 )(R 13 ). In embodiments, R 4 is independently -N(R 14 )C(0)R 15 . In embodiments, R 4 is independently -S(0) 2 R 15 .
- R 4 is independently C2-6alkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently C2-6alkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Ci- 6 haloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently C3-i2cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently -CH2-C3- ncycloalkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently Ci- li heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently -CH2-C1- li heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently C6-i2aryl optionally substituted with one, two, or three R 20a .
- R 4 is independently -CH 2 -C6-i2aryl optionally substituted with one, two, or three R 20a .
- R 4 is independently -CtC-Ci-nheteroaryl optionally substituted with one, two, or three R 20a .
- R 4 is independently Ci-nheteroaryl optionally substituted with one, two, or three R 20a .
- L 2 is a bond. In embodiments, L 2 is Ci-Cealkyl. In embodiments, L 2 is -0-. In embodiments, L 2 is -N(R 14 )-. In embodiments, L 2 is -C(O)-. In embodiments, L 2 is -N(R 14 )C(0)-. In embodiments, L 2 is -C(0)N(R 14 )-. In embodiments, L 2 is -S-. In embodiments, L 2 is -S(0) 2 -. In embodiments, L 2 is -S(O)-. In embodiments, L 2 is -S(0) 2 N(R 14 )-.
- L 2 is -S(0)N(R 14 )-. In embodiments, L 2 is -N(R 14 )S(0)-. In embodiments, L 2 is -N(R 14 )S(0) 2 -. In embodiments, L 2 is -OCON(R 14 )-. In embodiments, L 2 is -N(R 14 )C(0)0-. In embodiments, L 2 is -N(R 14 )C(0)N(R 14 )-. In embodiments, L 2 is -N(H)-. In embodiments, L 2 is -N(H)C(0)-. In embodiments, L 2 is -C(0)N(H)-. In embodiments, L 2 is -S(0) 2 N(H)-.
- L 2 is -S(0)N(H)-. In embodiments, L 2 is -N(H)S(0)-. In embodiments, L 2 is -N(H)S(0) 2 -. In embodiments, L 2 is -OCON(H)-. In embodiments, L 2 is -N(H)C(0)0-. In embodiments, L 2 is -N(H)C(0)N(R 14 )-.
- R 4 is independently Cialkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently C2alkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cialkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cialkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cialkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cealkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently C2alkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cialkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cialkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Csalkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cealkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently C2alkynyl optionally substituted with one, two, or three R 20a .
- R 4 is independently Cialkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cialkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Csalkynvi optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cealkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihaloalkyl. In embodiments, R 4 is independently Cihaloalkyl. In embodiments, R 4 is independently Cihaloalkyl. In embodiments, R 4 is independently Cihaloalkyl. In embodiments, R 4 is independently Cihaloalkyl. In embodiments, R 4 is independently Cihaloalkyl. In embodiments, R 4 is independently Cehaloalkyl. In embodiments, R 4 is independently Cehaloalkyl.
- R 4 is independently Ci cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cicycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cecycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently C7cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Ciocyclo
- R 4 is independently Cihetcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihetcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihetcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihetcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Ceheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently Ciheterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Gsaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently C-arvl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Csaryl optionally substituted with one, two, or three R 20a .
- R 4 is independently Csaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cioaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cnaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cnaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a .
- R 4 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Ceheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Csheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cioheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently Cioheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is
- R 4 is independently 3 membered cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 4 membered cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 5 membered cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 6 membered cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 7 membered cycloalkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently 8 membered cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 9 membered cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 10 membered cycloalkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently 3 membered heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 4 membered heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 5 membered heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 6 membered heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 7 membered heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 4 is independently 8 membered heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 9 membered heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 10 membered heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 6 membered aryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 7 membered aryl optionally substituted with one, two, or three R 20a .
- R 4 is independently 8 membered aryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 9 membered aryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 10 membered aryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 11 membered aryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 12 membered aryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 5 membered heteroaryl optionally substituted with one, two, or three R 20a .
- R 4 is independently 6 membered heteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 7 membered heteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 8 membered heteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 9 membered heteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 10 membered heteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 11 membered heteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 4 is independently 12 membered heteroaryl optionally substituted with one, two, or three R 20a .
- R 4 is independently -OH. In embodiments, R 4 is independently -SH. In embodiments, R 4 is independently -NH 2 . In embodiments, R 4 is independently -C(0)OH. In embodiments, R 4 is independently - OC(0)NH 2 . In embodiments, R 4 is independently -N(H)C(0)NH 2 . In embodiments, R 4 is independently - N(H)C(0)OH. In embodiments, R 4 is independently -N(H)S(0) 2 CH 3 . In embodiments, R 4 is independently - C(0)H. In embodiments, R 4 is independently -S(0)CH 3 . In embodiments, R 4 is independently -0C(0)CH 3 .
- R 4 is independently -OCH 3 . In embodiments, R 4 is independently -SCH 3 . In embodiments, R 4 is independently - N(CH 3 )(H). In embodiments, R 4 is independently -C(0)0CH 3 . In embodiments, R 4 is independently - 0C(0)N(CH 3 )(H). In embodiments, R 4 is independently -N(H)C(0)N(CH 3 )(H). In embodiments, R 4 is independently -N(H)C(0)0CH 3 . In embodiments, R 4 is independently -N(H)S(0) 2 CH 3 . In embodiments, R 4 is independently -C(0)CH 3 . In embodiments, R 4 is independently -S(0)CH 3 .
- R 4 is independently -CH 2 N(H)C(0)CH 3 . In embodiments, R 4 is independently -CH 2 S(0) 2 CH 3 . In embodiments, R 4 is independently and -CH 2 S(0) 2 N(CH 3 )(H). In embodiments, R 4 is independently -0C(0)N(CH 3 ) 2 . In embodiments, R 4 is independently -N(H)C(0)N(CH 3 ) 2 . In embodiments, R 4 is independently -C(0)(CH 3 ). In embodiments, R 4 is independently -C(0)N(CH 3 ) 2 . In embodiments, R 4 is independently -C(0)C(0)N(CH 3 ) 2 . In embodiments, R 4 is independently -C(0)C(0)N(CH 3 ) 2 .
- R 4 is capable of forming a covalent bond with the 12 th amino acid of a G12D KRas mutant. In embodiments, R 4 is capable of forming a covalent bond with the 12 th amino acid of a G12C KRas mutant. In embodiments, R 4 is capable of forming a covalent bond with the 12 th amino acid of a G12S KRas mutant. In embodiments, R 4 is capable of forming a covalent bond with the 13 th amino acid of a G13D KRas mutant. In embodiments, R 4 is capable of forming a covalent bond with the 13 th amino acid of a G13C KRas mutant. In embodiments, R 4 is capable of forming a covalent bond with the 13 th amino acid of a G13S KRas mutant.
- R 4 is selected from the group consisting of
- each R b is independently hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3- 6cycloalkyl, C2-7carboalkyl, C2-7carboxyalkyl, phenyl, or phenyl optionally substituted with one or more halogen, Ci- 6alkoxy, trifluoromethyl, amino, Ci-3alkylamino, C2-6dialkylamino, nitro
- R 4 is independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkoxy, and C1-C6 alkyl, or two R b are optionally join to form heterocycle having 3-12 ring atoms or C3-C6 cycloalkyl. In embodiments, R 4 is independently selected from the group consisting of
- R 4 is independently -C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , or -C(0)R 15 . In embodiments, R 4 is independently -C(0)N(R 12 )(R 13 ). In embodiments, R 4 is independently -N(R 14 )C(0)R 15 . In embodiments, R 4 is independently -C(0)R 15 .
- R 15 is C2-6alkenyl optionally substituted with one, two, or three R 20f , - C(0)R 15 wherein R 15 is C2-6alkynyl optionally substituted with one, two, or three R 20f , -C(0)R 15 wherein R 15 is C3- 6cycloalkyl optionally substituted with one, two, or three R 20f , -C(0)R 15 wherein R 15 is C2-9heterocycloalkyl optionally substituted with one, two, or three R 20f , -C(0)R 15 wherein R 15 is C 6 -ioaryl optionally substituted with one, two, or three R 20f , and -C(0)R 15 wherein R 15 is Ci-dictcroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)NH(R 12 ) and R 12 is independently Ci-dictcroaryl. wherein Ci- ihctcroaiyl is optionally substituted with one, two, or three R 20d .
- R 4 is independently - C(0)NH(R 12 ) and R 12 is independently Ci-shctcroan l. wherein Ci-shctcroaiy l is optionally substituted with one, two, or three R 20d .
- R 4 is independently -C(0)NH(R 12 ) and R 12 is independently Ci-ihctcroaryl.
- R 12 is independently Cialkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently C2alkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently C2alkenyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkcnyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkcnyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkcnyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cealkenyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently C2alkynyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cialkynyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cialkynyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Csalkynyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cealkynyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cihaloalkyl. In embodiments, R 12 is independently Cihaloalkyl.
- R 12 is independently Cihaloalkyl. In embodiments, R 12 is independently Cihaloalkyl. In embodiments, R 12 is independently Cshaloalkyl. In embodiments, R 12 is independently Cehaloalkyl.
- R 12 is independently Cscycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cicycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cscycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cecycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently C7cycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cscycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cscycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Ciocycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cdictcrocycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cdictcrocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Ceheterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently C-hetcrocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cearyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently C-aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Csaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Csaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cioaryl optionally substituted with one, two, or three R 20d .
- R 12 is independently Cnaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cnaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cihctcroaiyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cihctcroaiyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cihctcroaiy l optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently C die tcro aryl optionally substituted with one, two, or three R 20d .
- R 12 is independently Ceheteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently C 7 he tcro aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Csheteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cihctcroaiy l optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cioheteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently Cnheteroaryl optionally substituted with one, two, or three R 20d .
- R 12 is independently 3 membered cycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 4 membered cycloalkyl optionally substituted with one, two, or three
- R 20d is independently 5 membered cycloalkyl optionally substituted with one, two, or three
- R 12 is independently 6 membered cycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 7 membered cycloalkyl optionally substituted with one, two, or three
- R 20d is independently 8 membered cycloalkyl optionally substituted with one, two, or three
- R 20d is independently 9 membered cycloalkyl optionally substituted with one, two, or three
- R 20d is independently 10 membered cycloalkyl optionally substituted with one, two, or three
- R 12 is independently 3 membered heterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 4 membered heterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 5 membered heterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 6 membered heterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 7 membered heterocycloalkyl optionally substituted with one, two, or three R 20d .
- R 12 is independently 8 membered heterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 9 membered heterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 10 membered heterocycloalkyl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 6 membered aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 7 membered aryl optionally substituted with one, two, or three R 20d .
- R 12 is independently 8 membered aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 9 membered aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 10 membered aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 11 membered aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 12 membered aryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 5 membered heteroaryl optionally substituted with one, two, or three R 20d .
- R 12 is independently 6 membered heteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 7 membered heteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 8 membered heteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 9 membered heteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 10 membered heteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 11 membered heteroaryl optionally substituted with one, two, or three R 20d . In embodiments, R 12 is independently 12 membered heteroaryl optionally substituted with one, two, or three R 20d .
- R 15 is independently Cialkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C2alkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cialkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cialkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Csalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cealkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently C2alkenyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Ci alkenyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C4alkenyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Csalkcnyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cealkenyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C2alkynyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cialkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C4alkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Csalkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cealkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cihaloalkyl. In embodiments, R 15 is independently Cihaloalkyl.
- R 15 is independently Cihaloalkyl. In embodiments, R 15 is independently Cihaloalkyl. In embodiments, R 15 is independently Cshaloalkyl. In embodiments, R 15 is independently Cehaloalkyl.
- R 15 is independently Cscycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cicycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cscycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cecycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently C7cycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cscycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cscycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Ciocycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cdictcrocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Ceheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C-hetcrocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cearyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C-aiyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Csaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Csaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cioaryl optionally substituted with one, two, or three R 20f .
- R 15 is independently Cnaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cearyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cihctcroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cihctcroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cihctcroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cshctcroarvl optionally substituted with one, two, or three R 20f .
- R 15 is independently Ceheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C-hetcroarvl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Csheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cdictcroarvl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cioheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Cnheteroaryl optionally substituted with one, two, or three R 20f .
- R 15 is independently 3 membered cycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 4 membered cycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 5 membered cycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 6 membered cycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 7 membered cycloalkyl optionally substituted with one, two, or three R 20f .
- R 20f is independently 8 membered cycloalkyl optionally substituted with one, two, or three
- R 20f is independently 9 membered cycloalkyl optionally substituted with one, two, or three
- R 20f is independently 10 membered cycloalkyl optionally substituted with one, two, or three
- R 15 is independently 3 membered heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 4 membered heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 5 membered heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 6 membered heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 7 membered heterocycloalkyl optionally substituted with one, two, or three R 20f .
- R 15 is independently 8 membered heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 9 membered heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 10 membered heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 6 membered aryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 7 membered aryl optionally substituted with one, two, or three R 20f .
- R 15 is independently 8 membered aryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 9 membered aryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 10 membered aryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 11 membered aryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 12 membered aryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 5 membered heteroaryl optionally substituted with one, two, or three R 20f .
- R 15 is independently 6 membered heteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 7 membered heteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 8 membered heteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 9 membered heteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 10 membered heteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 11 membered heteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently 12 membered heteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently selected from C2-6alkenyl, C2- 6 alkynyl, C2-s>heterocycloalkyl, and C’ l -yhctcroarvl. wherein C2-6alkenyl, C2-6alkynyl, C2-s>heterocycloalkyl, and Ci- yhctcroarvl are optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently C2alkenyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently Cialkcnyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Cialkcnyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Csalkcnyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Cealkenyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently C2alkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Cialkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Cialkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently - C(0)R 15 and R 15 is independently Csalkynyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently Cealkynyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently Cohctcrocycloalkyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20f .
- R 4 is independently - C(0)R 15 and R 15 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Ceheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently C-hctcrocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Csheterocycloalkyl optionally substituted
- R 4 is independently -C(0)R 15 and R 15 is independently Ciheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Ciheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Ciheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Ciheteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -C(0)R 15 and R 15 is independently Cshctcroarvl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Ceheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Ciheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Csheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -C(0)R 15 and R 15 is independently Ceheteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently selected from C2-6alkenyl, C2- 6 alkynyl, C2-9heterocycloalkyl, and C’ l -dictcroarvl. wherein C2-6alkenyl, C2-6alkynyl, C2-9heterocycloalkyl, and Ci- eheteroaryl are optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently C2alkenyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Cialkcnyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Cialkcnyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Csalkcnyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Cealkenyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently C2alkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Csalkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Cialkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Csalkynyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Cealkynyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently C 2 heterocycloalkyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently C3heterocycloalkyl optionally substituted with one, two, or three R 20f .
- R 4 is independently - NHC(0)R 15 and R 15 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Cshctcrocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Ceheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently - NHC(0)R 15 and R 15 is independently C7heterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Cdictcrocycloalkyl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Ciheteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently C 2 heteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Cihctcroarvl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Ciheteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Cshctcroarvl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Ceheteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently C7heteroaryl optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -NHC(0)R 15 and R 15 is independently Csheteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is independently -NHC(0)R 15 and R 15 is independently Csheteroaryl optionally substituted with one, two, or three R 20f .
- R 4 is capable of forming a covalent bond with a Ras amino acid sidechain. In embodiments, R 4 is capable of forming a covalent bond with a KRas amino acid. In embodiments, R 4 is capable of forming a covalent bond with the 12 th amino acid of a human KRas protein. In embodiments, R 4 is capable of forming a covalent bond with the 12 th amino acid of a mutant KRas protein selected from KRas G12D, KRas G12C, and KRas G12S. In embodiments, R 4 is capable of forming a covalent bond with the 13 th amino acid of a human KRas protein. In embodiments, R 4 is capable of forming a covalent bond with the 13 th amino acid of a mutant KRas protein selected from KRas G13D, KRas G13C, and KRas G13S.
- R 4 is selected from
- R 4 is selected from
- R 15 is independently C 2-6 alkenyl optionally substituted with one, two, or three
- R 15 is independently C 2-6 alkenyl optionally substituted with one, two, or three halogen. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with one, two, or three F. In embodiments,
- R 15 is independently C 2-6 alkenyl optionally substituted with -OR 21 . In embodiments, R 15 is independently C 2 - 6alkenyl optionally substituted with -N(R 22 )(R 23 ). In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with C 2-9 heterocycloalkyl. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with Ci- 5 heteroaryl optionally substituted with one, two, or three Ci-6alkyl. In embodiments, R 15 is independently C 2 - 6alkenyl optionally substituted with Ci-shctcroarvl optionally substituted with methyl.
- R 15 is independently C 2-6 alkenyl optionally substituted with -CN. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with Ci-shctcroarvl optionally substituted with -N(R 24 )C(0)R 25 . In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with Ci- hctcroarvl and/or CN. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with one, two, or three halogen.
- R 15 is independently C 2-6 alkenyl optionally substituted with one, two, or three F. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with -OR 21 . In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with -N(R 22 )(R 23 ). In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with C 2-9 heterocycloalkyl. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with Ci-shctcroarvl optionally substituted with one, two, or three Ci-6alkyl.
- R 15 is independently C 2-6 alkenyl optionally substituted with Ci-shctcroarvl optionally substituted with methyl. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with - CN. In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with Ci-shctcroarvl optionally substituted with -N(R 24 )C(0)R 25 . In embodiments, R 15 is independently C 2-6 alkenyl optionally substituted with - C(0)N(R 22 )(R 23 ). In embodiments, R 15 is independently C 2-6 alkenyl substituted with Cl and optionally substituted with one or two R 20f .
- R 15 is independently C 2-6 alkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with one, two, or three halogen. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with one, two, or three F. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with -OR 21 . In embodiments, R 15 is independently C 2 - 6alkynyl optionally substituted with -N(R 22 )(R 23 ). In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with C 2-9 heterocycloalkyl.
- R 15 is independently C 2-6 alkynyl optionally substituted with Ci-sheteroaryl optionally substituted with one, two, or three Ci-6alkyl. In embodiments, R 15 is independently C 2 - 6alkynyl optionally substituted with Ci-shctcroarvl optionally substituted with methyl. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with -CN. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with Ci-sheteroaryl optionally substituted with -N(R 24 )C(0)R 25 .
- R 15 is independently C 2-6 alkynyl optionally substituted with Ci-sheteroaryl and/or CN. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with one, two, or three halogen. In embodiments, R 15 is independently C 2 - 6 alkynyl optionally substituted with one, two, or three F. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with -OR 21 . In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with - N(R 22 )(R 23 ).
- R 15 is independently C 2-6 alkynyl optionally substituted with C 2 -s > heterocycloalkyl. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with C’ l -shctcroarvl optionally substituted with one, two, or three Ci- 6 alkyl. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with Ci- sheteroaryl optionally substituted with methyl. In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with -CN.
- R 15 is independently C 2-6 alkynyl optionally substituted with C’ l -shctcroarvl optionally substituted with -N(R 24 )C(0)R 25 . In embodiments, R 15 is independently C 2-6 alkynyl optionally substituted with -C(0)N(R 22 )(R 23 ). In embodiments, R 15 is independently C 2-6 alkynyl substituted with Cl and optionally substituted with one or two R 20f . In embodiments, R 15 is independently C 3 -scycloalkyl, optionally substituted with one, two, or three R 20f .
- R 15 is independently C 3 -scycloalkyl, optionally substituted with Ci- 6 alkyl optionally substituted with one, two, or three halogen. In embodiments, R 15 is independently C 3 - scycloalkyl, optionally substituted with Ci- 6 alkyl optionally substituted with one, two, or three F. In embodiments, R 15 is independently Ci-shctcrocycloalkyl. optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Ci-shctcrocycloalkyl. optionally substituted with Ci- 6 alkyl optionally substituted with one, two, or three halogen.
- R 15 is independently Ci-shctcrocycloalkyl. optionally substituted with Ci- 6 alkyl optionally substituted with one, two, or three F. In embodiments, R 15 is independently Ci- 6 alkyl, optionally substituted with one, two, or three R 20f . In embodiments, R 15 is independently Ci- 6 alkyl, substituted with Cl and optionally substituted with one, two, or three R 20f . In embodiments, R 4 is independently -CN.
- L 2 is independently a bond, -C(0)NH-, -NHC(O)-, or -C(O)-; and R 5 is independently selected from halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -i 2 cycloalkyl, -CFF-Cs-ncycloalkyl, Ci- li heterocycloalkyl, -CFF-Ci-nheterocycloalkyl, Gs-naryl, -CH 2 -C 6 -i 2 aryl, -CFF-Ci-nheteroaryl, Ci-nheteroaryl, - OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ;
- L 2 is independently -C(O)-; and R 5 is independently a Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -i 2 cycloalkyl, -CH 2 -C 3 -i 2 cycloalkyl, Ci-nheterocycloalkyl, -CFF-Ci-nheterocycloalkyl, C 6 -i 2 aryl, -CH 2 -C 6 -i 2 aryl, - CH 2 -Ci-nheteroaryl, or Ci-nheteroaryl, wherein the Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -i 2 cycloalkyl, -CH 2 -C 3 - ncycloalkyl, Ci-nheterocycloalkyl, -CFF-Ci-nheterocycloalkyl, C 6 -
- L 2 is independently -C(O)-; and R 5 is independently a C 3 -i 2 cycloalkyl, Ci- li heterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl, wherein the C 3 -i 2 cycloalkyl, Ci-nheterocycloalkyl, C 6 -i 2 aryl, and Ci- nheteroaryl are optionally substituted with one, two, or three R 20a .
- L 2 is independently a bond, -C(0)NH-, -NHC(O)-, or -C(O)-; L 2 is independently bonded to a carbon atom of R 5 ; and R 5 is independently selected from -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3- ncycloalkyl, C6-i2aryl, and Ci-nheteroaryl, wherein C h alky 1, C2-6alkenyl, C2-6alkynyl, C3-i2cycloalkyl, Gs-naryl, and Ci-iiheteroaryl, are optionally substituted with one, two, or three R 20a .
- L 2 is independently -C(O)-; L 2 is independently bonded to a carbon atom of R 5 ; and R 5 is independently selected from Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-i2cycloalkyl, C6-i2aryl, and Ci-nheteroaryl, wherein the C h alky 1, C2-6alkenyl, C2-6alkynyl, C3-i2cycloalkyl, Gs-naryl, and Ci-nheteroaryl, are optionally substituted with one, two, or three R 20a .
- L 2 is independently -C(O)-; L 2 is independently bonded to a carbon atom of R 5 ; and R 5 is independently selected from Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, and 5-6 membered heteroaryl, wherein the Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, and 5-6 membered heteroaryl are optionally substituted with one, two, or three R 20a .
- L 2 is independently -C(O)-;
- R 5 is independently ;
- R 5a is independently CH, C(R 20a ), CH(R 20a ), QH, C(R 20a )2, N, NH, or N(R 20a );
- R 5 comprises 0-3 independent R 20a ; and
- 0-4 R 5a are independently N, NH, or N(R 20a ).
- L 2 is independently -C(O)-; and R 5 is independently C3-iocycloalkyl, wherein C3- l ocycloalkyl is independently optionally substituted with one, two, or three R 20a .
- L 2 is independently -C(O)-; and R 5 is independently cyclopropyl, wherein cyclopropyl is independently optionally substituted with one, two, or three F.
- L 2 is independently -C(O)-; and R 5 is independently cyclopropyl, wherein cyclopropyl is independently optionally substituted with one, two, or three CN.
- L 2 is independently -C(O)-; and R 5 is independently cyclopropyl, wherein cyclopropyl is independently optionally substituted with one, two, or three halogen.
- R 5 is independently hydrogen. In embodiments, R 5 is independently halogen. In embodiments, R 5 is independently R 5 is independently oxo. In embodiments, R 5 is independently -CN. In embodiments, R 5 is independently Ci- 6 alkyl. In embodiments, R 5 is independently C2-6alkenyl. In embodiments, R 5 is independently C2-6alkynyl. In embodiments, R 5 is independently Ci- 6 haloalkyl. In embodiments, R 5 is independently C3-i2cycloalkyl. In embodiments, R 5 is independently -CH 2 -C3-i2cycloalkyl. In embodiments, R 5 is independently Ci-nheterocycloalkyl.
- R 5 is independently -QH-Ci-nheterocycloalkyl. In embodiments, R 5 is independently C6-i2aryl. In embodiments, R 5 is independently -CH 2 -C6-i2aryl. In embodiments, R 5 is independently -Cfh-Ci-nheteroaryl. In embodiments, R 5 is independently Ci-nheteroaryl. In embodiments,
- R 5 is independently -OR 12 . In embodiments, R 5 is independently -SR 12 . In embodiments, R 5 is independently - N(R 12 )(R 13 ). In embodiments, R 5 is independently -C(0)0R 12 . In embodiments, R 5 is independently - 0C(0)N(R 12 )(R 13 ). In embodiments, R 5 is independently -N(R 15 )C(0)N(R 12 )(R 13 ). In embodiments, R 5 is independently -N(R 15 )C(0)0R 15 . In embodiments, R 5 is independently -N(R 15 )S(0) 2 R 15 . In embodiments, R 5 is independently -C(0)R 15 .
- R 5 is independently -CH 2 C(0)N(R 12 )(R 13 ). In embodiments, R 5 is independently -CH 2 N(R 15 )C(0)R 15 . In embodiments, R 5 is independently -CH 2 S(0) 2 R 15 . In embodiments, R 5 is independently and -CH 2 S(0) 2 N(R 12 )(R 13 ). In embodiments, R 5 is independently Ci- 6 alkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently C2-6alkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently C2-6alkynyl optionally substituted with one, two, or three R 20a .
- R 5 is independently Ci- 6 haloalkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently C3-i2cycloalkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently -CH 2 -C3-i2cycloalkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently Ci-nheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently -Cfh-Ci-nheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently C6-i2aryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently -CH 2 -C6-i2aryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently -Cfh-Ci-nheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cmheteroaryl optionally substituted with one, two, or three R 20a .
- R 5 is independently selected from hydrogen, halogen, oxo, -CN, Ci-ealkyl, C 2-6 alkenyl, C 2-6 alkynyl, -OR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), and -C(0)R 12 , wherein Ci- 6 alkyl, C2-6alkenyl, and C2-6alkynyl, are optionally substituted with one, two, or three R 20a .
- R 5 is independently hydrogen.
- R 5 is independently halogen.
- R 5 is independently oxo. In some embodiments of the subject compound, R 5 is independently -CN. In additional embodiments of the subject compound, R 5 is independently Ci- 6 alkyl. In embodiments of the subject compound, R 5 is independently C 2 - 6 alkenyl. In some embodiments of the subject compound, R 5 is independently C2-6alkynyl. In further embodiments of the subject compound, R 5 is independently -OR 12 . In select embodiments of the subject compound, R 5 is independently -N(R 12 )(R 13 ). In additional embodiments of the subject compound, R 5 is independently -C(0)0R 12 .
- R 5 is independently -0C(0)N(R 12 )(R 13 ). In some embodiments of the subject compound, R 5 is independently -C(0)R 12 . In select embodiments of the subject compound, R 5 is independently -NH 2 . In further embodiments of the subject compound, R 5 is independently -C(0)0H. In additional embodiments of the subject compound, R 5 is independently -0C(0)NH 2 . In embodiments of the subject compound, R 5 is independently -C(0)CH 3 .
- R 5 is independently Cialkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently C2alkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cialkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cialkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Csalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cealkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently C2alkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cialkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cialkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Csalkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cealkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently C2alkynyl optionally substituted with one, two, or three R 20a .
- R 5 is independently Cialkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cialkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Chalky m l optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cealkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cihaloalkyl. In embodiments, R 5 is independently C2haloalkyl. In embodiments, R 5 is independently Cihaloalkyl. In embodiments, R 5 is independently Cihaloalkyl. In embodiments, R 5 is independently Cshaloalkyl. In embodiments, R 5 is independently Cehaloalkyl. In embodiments, R 5 is independently Cehaloalkyl.
- R 5 is independently Cicycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cicycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cecycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently C7cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Ciocycloal
- R 5 is independently C2heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cshetcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Ceheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently C-hetcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 5 is independently Cearyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently C-arvl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Csaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Csaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cioaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cnaryl optionally substituted with one, two, or three R 20a .
- R 5 is independently Cearyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently C2heteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cshctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Ceheteroaryl optionally substituted with one, two, or three R 20a .
- R 5 is independently C-hctcroaiy l optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Csheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cdictcroaiyl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cioheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently Cnheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 5 is independently -OH. In embodiments, R 5 is independently -SH.
- R 5 is independently -NH 2 . In embodiments, R 5 is independently -C(0)0H. In embodiments, R 5 is independently - 0C(0)NH 2 . In embodiments, R 5 is independently -N(H)C(0)NH 2 . In embodiments, R 5 is independently - N(H)C(0)0H. In embodiments, R 5 is independently -N(H)S(0) 2 CH . In embodiments, R 5 is independently - C(0)H. In embodiments, R 5 is independently -S(0)CH . In embodiments, R 5 is independently -0C(0)CH 3 . In embodiments, R 5 is independently -C(0)NH 2 . In embodiments, R 5 is independently -C(0)C(0)NH 2 .
- R 5 is independently -OCH 3 . In embodiments, R 5 is independently -SCH 3 . In embodiments, R 5 is independently -N(CH 3 )(H). In embodiments, R 5 is independently -C(0)0CH 3 . In embodiments, R 5 is independently -0C(0)N(CH 3 )(H). In embodiments, R 5 is independently -N(H)C(0)N(CH 3 )(H). In embodiments, R 5 is independently -N(H)C(0)0CH 3 . In embodiments, R 5 is independently -N(H)S(0) 2 CH 3 . In embodiments, R 5 is independently -C(0)CH 3 . In embodiments, R 5 is independently -S(0)CH 3 .
- R 5 is independently -CH 2 N(H)C(0)CH 3 . In embodiments, R 5 is independently -CH 2 S(0) 2 CH 3 . In embodiments, R 5 is independently and -CH 2 S(0) 2 N(CH 3 )(H).
- R 5 is independently -CH 3 . In embodiments, R 5 is independently -CF 3 . In embodiments, R 5 is independently -CHF 2 . In embodiments, R 5 is independently -CFH 2 . In embodiments, R 5 is independently ethyl. In embodiments, R 5 is independently propyl. In embodiments, R 5 is independently isopropyl. In embodiments, R 5 is independently butyl. In embodiments, R 5 is independently tert-butyl.
- R 6 is independently halogen. In embodiments, R 6 is independently R 6 is independently oxo. In embodiments, R 6 is independently -CN. In embodiments, R 6 is independently Ci- 6 alkyl. In embodiments, R 6 is independently C 2-6 alkenyl. In embodiments, R 6 is independently C 2-6 alkynyl. In embodiments, R 6 is independently Ci- 6 haloalkyl. In embodiments, R 6 is independently C 3 -i 2 cycloalkyl. In embodiments, R 6 is independently -CH 2 -C 3 -i 2 cycloalkyl. In embodiments, R 6 is independently Ci-nheterocycloalkyl. In embodiments, R 6 is independently -Cfh-Ci-nheterocycloalkyl. In embodiments, R 6 is independently C6-i2aryl. In embodiments,
- R 6 is independently -CH 2 -C6-i2aryl. In embodiments, R 6 is independently -Cfh-Ci-nheteroaryl. In embodiments, R 6 is independently Ci-nheteroaryl. In embodiments, R 6 is independently -OR 12 . In embodiments, R 6 is independently -SR 12 . In embodiments, R 6 is independently -N(R 12 )(R 13 ). In embodiments, R 6 is independently -C(0)0R 12 . In embodiments, R 6 is independently -0C(0)N(R 12 )(R 13 ). In embodiments, R 6 is independently - N(R 16 )C(0)N(R 12 )(R 13 ).
- R 6 is independently -N(R 16 )C(0)0R 15 . In embodiments, R 6 is independently -N(R 16 )S(0) 2 R 15 . In embodiments, R 6 is independently -C(0)R 15 . In embodiments, R 6 is independently -S(0)R 15 . In embodiments, R 6 is independently -0C(0)R 15 . In embodiments, R 6 is independently - C(0)N(R 12 )(R 13 ). In embodiments, R 6 is independently -C(0)C(0)N(R 12 )(R 13 ). In embodiments, R 6 is independently -N(R 16 )C(0)R 15 . In embodiments, R 6 is independently -S/CfhR 15 .
- R 6 is independently C2-6alkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 6 is independently C2-6alkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 6 is independently Ci- 6 haloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 6 is independently C3- ncycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 6 is independently -CH2-C3- ncycloalkyl optionally substituted with one, two, or three R 20a .
- R 6 is independently Ci- li heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 6 is independently -CH2-C1- li heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 6 is independently C6-i2aryl optionally substituted with one, two, or three R 20a .
- R 6 is independently -CH 2 -C6-i2aryl optionally substituted with one, two, or three R 20a .
- R 6 is independently -Cfh-Ci-nheteroaryl optionally substituted with one, two, or three R 20a .
- R 6 is independently Ci-nheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently hydrogen. In select embodiments of the compound, R 1 is independently Ci- 6 alkyl optionally substituted with one, two, or three R 20a . In embodiments of the compound, R 1 is independently methyl optionally substituted with one or two R 20a . In further embodiments of the compound, R 1 is independently methyl. In some embodiments of the compound, R 1 is independently ethyl optionally substituted with one, two, or three R 20a . In embodiments of the compound, R 1 is independently ethyl. In some embodiments of the compound, R 1 is independently propyl optionally substituted with one, two, or three R 20a . In embodiments of the compound, R 1 is independently propyl.
- R 1 is independently -CH2-C2- dictcrocycloalkyl optionally substituted with one, two, or three R 20a . In some embodiments, R 1 is independently - CH2-(monocyclic C2-8heterocycloalkyl) optionally substituted with one, two, or three R 20a . In some embodiments,
- R 1 is independently -CH2-(monocyclic C3-5heterocycloalkyl) optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH2-(spirocyclic C2-nheterocycloalkyl) optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH2-(spirocyclic C3-iiheterocycloalkyl) optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH2-(fused C2- li heterocycloalkyl) optionally substituted with one, two, or three R 20a .
- R 1 is independently - CH2-(spirocyclic Ce-sheterocycloalkyl) optionally substituted with one, two, or three R 20a .
- R 1 is independently Ci- 6 alkyl.
- R 1 is independently C2-6alkenyl.
- R 1 is independently C2- 6alkynyl.
- R 1 is independently C 3 -iocycloalkyl.
- R 1 is independently -CH 2 -C 3 - l ocycloalkyl.
- R 1 is independently C 2-9 heterocycloalkyl.
- R 1 is independently - CH 2 -C 2-9 heterocycloalkyl.
- R 1 is independently C6-ioaryl. In embodiments, R 1 is independently - CH 2 -C6-ioaryl. In embodiments, R 1 is independently -CEb-Ci-gheteroaryl. In embodiments, R 1 is independently Ci- gheteroaryl. In embodiments, R 1 is independently Ci-6alkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently C 2-6 alkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently C 2-6 alkynyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C 3 -iocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CH 2 -C 3 -iocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently C 2-9 heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CH 2 -C 2-9 heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently C6-ioaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently - CH 2 -C6-ioaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CH 2 -C 1 - gheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Ci-gheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently Ci-6alkyl. In embodiments, R 1 is independently C 2-6 alkenyl. In embodiments, R 1 is independently C 2-6 alkynyl. In embodiments, R 1 is independently Ci-6haloalkyl. In embodiments, R 1 is independently C 3 -i 2 cycloalkyl. In embodiments, R 1 is independently -CH 2 -C 3 -i 2 cycloalkyl. In embodiments, R 1 is independently Ci-nheterocycloalkyl. In embodiments, R 1 is independently -CH 2 -C 1 - li heterocycloalkyl. In embodiments, R 1 is independently C 6 -i 2 aryl.
- R 1 is independently -CH 2 -C 6 - naryl. In embodiments, R 1 is independently -CEC-Ci-nheteroaryl. In embodiments, R 1 is independently Ci- nheteroaryl.
- R 1 is independently Ci-6alkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C 2-6 alkenyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C 2-6 alkynyl optionally substituted with one, two, or three R 20a .
- R 1 is independently Ci-6haloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C 3 -i 2 cycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 3 - ncycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently Ci- li heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 1 - li heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C 6 -i 2 aryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 6 -i 2 aryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -Qk-Ci-nheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Ci-nheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently Cialkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C 2 alkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C ialky l optionally substituted with one, two, or three R 20a .
- R 1 is independently Cialkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently Cialkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently Cealkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently C 2 alkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cialkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cialkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Csalkcnyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cealkenyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently C2alkynyl optionally substituted with one, two, or three R 20a .
- R 1 is independently Cialkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cialkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Csalkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cealkynyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihaloalkyl. In embodiments, R 1 is independently Cihaloalkyl. In embodiments, R 1 is independently Cihaloalkyl. In embodiments, R 1 is independently Cihaloalkyl. In embodiments, R 1 is independently Cihaloalkyl. In embodiments, R 1 is independently Cehaloalkyl. In embodiments, R 1 is independently Cehaloalkyl.
- R 1 is independently Ci cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cicycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cecycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently C7cycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Ciocyclo
- R 1 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cdictcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihctcrocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Ceheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently Cvheterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Csheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently Cearyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently C-arvl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Csaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Csaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cioaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cnaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently Cearyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Ceheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently C-hetcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Csheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cihctcroarvl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cioheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently Cnheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 3 cycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C4cycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CFF-Cscycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 6 cycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C7cycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CFF-Cscycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CFF-Cgcycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CH 2 -Ciocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 2 heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 3 heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C4heterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CFF-Csheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 6 heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CH 2 -C7heterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CFF-Csheterocycloalkyl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CFF-Csiheterocycloalkyl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 6 aryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C7aryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CFF-Csaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C9aryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -Cioaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -Cnaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -Ci 2 aryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 2 heteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C3heteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C4heteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CFF-Csheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C 6 heteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -C7heteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CFF-Csheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -Cs>heteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 2 -Cioheteroaryl optionally substituted with one, two, or three R 20a . In embodiments, R 1 is independently -CH 2 -Cnheteroaryl optionally substituted with one, two, or three R 20a .
- R 1 is independently -CH 3 . In embodiments, R 1 is independently -CF 3 . In embodiments, R 1 is independently -CHF 2 . In embodiments, R 1 is independently -CFH 2 . In embodiments, R 1 is independently ethyl. In embodiments, R 1 is independently propyl. In embodiments, R 1 is independently isopropyl. In embodiments, R 1 is independently butyl. In embodiments, R 1 is independently tert-butyl. [00313] In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 7 p is an integer from 0 to 12;
- R 7 is p is an integer from 0 to 12;
- R 7 is
- R 16 is independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl are optionally substituted with one, two, or three R 20g .
- R 16 is independently selected from hydrogen and halogen.
- R 16 is independently selected from hydrogen and fluoro. In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 16 is hydrogen. In embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 16 is fluoro.
- R 8 is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, and C 2-9 heterocycloalkyl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, and C 2-9 heterocycloalkyl are optionally substituted with one, two, or three R 20c .
- R 8 is selected from hydrogen, Ci- 6 alkyl, C 3 -iocycloalkyl, and C 2-9 heterocycloalkyl, wherein Ci- 6 alkyl, C 3 -iocycloalkyl, and C 2-9 heterocycloalkyl are optionally substituted with one, two, or three R 20c independently selected from halogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2 - 6alkynyl, C 3 -iocycloalkyl, and C 2-9 heterocycloalkyl.
- R 8 is selected from hydrogen, methyl, cyclopropyl, cyclobutyl, and oxetanyl, wherein said methyl, cyclopropyl, cyclobutyl, and oxetanyl are optionally substituted with one, two, or three R 20c independently selected from fluoro, methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 8 is selected from hydrogen, methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 8 is selected from halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -N(
- R 8 is selected from Ci- 6 alkyl, C3-iocycloalkyl, and C2-s>heterocycloalkyl, wherein Ci- 6 alkyl, C3-iocycloalkyl, and C2-s>heterocycloalkyl are optionally substituted with one, two, or three R 20c independently selected from halogen, Ci- 6 alkyl, C2- 6alkenyl, C2-6alkynyl, C3-iocycloalkyl, and C2-9heterocycloalkyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl, wherein said methyl, cyclopropyl, cyclobutyl, and oxetanyl are optionally substituted with one, two, or three R 20c independently selected from fluoro, methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 8 is selected from methyl, cyclopropyl, cyclobutyl, and oxetanyl.
- R 3 is hydrogen or CN. In additional embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 3 is hydrogen. In further embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 3 is CN.
- L 1 is a bond. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, L 1 is selected from a Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, -C(O)-, -NHC(O)-, -C(0)NH-,
- L 1 is a bond. In embodiments, L 1 is Ci-Cealkyl. In embodiments, L 1 is C2-C6alkenyl. In embodiments, L 1 is C2-C6alkynyl. In embodiments, L 1 is -0-. In embodiments, L 1 is -N(R 14 )-. In embodiments, L 1 is -C(O)-. In embodiments, L 1 is -N(R 14 )C(0)-. In embodiments, L 1 is -C(0)N(R 14 )-. In embodiments, L 1 is -S-. In embodiments, L 1 is -S(0) 2 -. In embodiments, L 1 is -S(O)-.
- L 1 is -S(0) 2 N(R 14 )-. In embodiments, L 1 is -S(0)N(R 14 )-. In embodiments, L 1 is -N(R 14 )S(0)-. In embodiments, L 1 is -N(R 14 )S(0) 2 -. In embodiments, L 1 is -OCON(R 14 )-. In embodiments, L 1 is - N(R 14 )C(0)0-. In embodiments, L 1 is N(R le ). In embodiments, L 1 is C(0)N(R lc ). In embodiments, L 1 is S(0) 2 N(R 1c ). In embodiments, L 1 is S(0)N(R lc ).
- L 1 is C(R lf )(R lg )0. In embodiments, L 1 is C(R lf )(R lg )N(R lc ). In embodiments, L 1 is C(R lf )(R lg ). In embodiments, L 1 is -N(H)-. In embodiments, L 1 is -N(H)C(0)-. In embodiments, L 1 is -C(0)N(H)-. In embodiments, L 1 is -S(0) 2 N(H)-. In embodiments, L 1 is -S(0)N(H)-. In embodiments, L 1 is -N(H)S(0)-. In embodiments, L 1 is -N(H)S(0) 2 -.
- L 1 is -OCON(H)-. In embodiments, L 1 is -N(H)C(0)0-. In embodiments, L 1 is -N(H)-.
- L 1 is -C(0)N(H)-. In embodiments, L 1 is -S(0) 2 N(H)-. In embodiments, L 1 is - S(0)N(H)-. In embodiments, L 1 is -CH2O-. In embodiments, L 1 is -CH 2 N(H)-. In embodiments, L 1 is -
- R 19 is a monocyclic ring. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is a bicyclic ring system. In some embodiments of the subject compound, or a pharmaceutically acceptable salt or solvate thereof, R 19 is a polycyclic ring system. In embodiments of the
- R 19 is: X 6
- Q 1 , Q 3 , and Q 5 are independently N or C(R ld );
- Q 4 and Q 6 are independently O, S, C(R la )(R lb ), or N(R lc );
- X 4 , X 5 , X 6 , X 9 , X 10 , X 11 , and X 12 are independently selected from C(R la ) or N;
- X 7 and X 8 are independently selected from C(R la ), C(R la )(R lb ), N, or N(R lc ); each R la , R lb , R ld , and R lh are each independently selected from hydrogen, halogen, -CN, CYr, alkyl. CY (Jialoalkyl. CYr, alkenyl. CYr,alkynyl.
- CYr alkenyl. CYr,alkynyl.
- C3-iocycloalkyl, C 2 -9heterocycloalkyl, Ce-ioaryl, and Ci-9heteroaryl are optionally substituted with one, two, or three R 201 ; or R la and R lb bonded to the same carbon are joined to form a 3-10 membered heterocycloalkyl ring or a C3-iocycloalkyl ring, wherein the 3-10 membered heterocycloalkyl ring or C3-iocycloalkyl ring are optionally substituted with one, two, or three R 201 ; or two R la bonded to adjacent atoms are joined to form a 3-10 membered heterocycloalkyl ring, a Ce-ioaryl ring, a 5-12 membered heteroaryl ring, or a C3-iocycloalkyl ring, wherein the 3-10 membered heterocycloal
- CYr alkenyl. CYr,alkynyl. C3-iocycloalkyl, C 2. 9heterocycloalkyl, Ce-ioaryl, Ci-9heteroaryl, wherein CYr, alkyl. CYr, alkenyl. CYr,alkynyl. C3- l ocycloalkyl, C 2-9 heterocycloalkyl, Ce-ioaryl, and Ci- 9 heteroaryl are optionally substituted with one, two, or three R 201 .
- R 2 is selected from
- each R 5 is independently selected from:
- W is C(0), S(0), or S(0) 2 ;
- V is C(R 16 ) or N;
- R 10 is -L 7 -R 7 ;
- V is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- R 7 is a 3-12 membered heterocycloalkyl or 5-12 membered heteroaryl, wherein the 3-12 membered heterocycloalkyl or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , one or more R 4 , or one or more R 6 ; two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i 2 cycloalkyl, Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl, wherein the C3- i 2 cycloalkyl.
- Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl are optionally substituted with one, two, or three R 20a ; each R 1 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci- 6 haloalkyl, C3- i 2 cycloalkyl.
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, G-Galkyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0) 2 R
- R 17 is -G-R 19 ;
- L 1 is selected from a bond, G-Galkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ), and
- R lc is selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, CV,. ioaryl, and Ci-dictcroarvl. wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201
- R 19 is selected from a C3-i2cycloalkyl, C2-nheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl, wherein the C3- ncycloalkyl, C2-iiheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3- 6cycloalkyl, C2-9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , - 0C(0)N(R 12 )(R
- R 16 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2- gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0)
- R 12a is selected from Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2- gheterocycloalkyl, -CH2-C2-9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH2-Ci-9heteroaryl, and Ci- gheteroaryl, wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, -CH2-C3-iocycloalkyl, C2- yhctcrocycloalkvl.
- Ci- gheteroaryl are optionally substituted with one, two, or three R 20d ;
- R 12b is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -CH 2 -C3-iocycloalkyl, C 2. gheterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -Ci-9heteroaryl, and Ci- gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -CH 2 -C3-iocycloalkyl, C 2.
- gheterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -Ci-9heteroaryl, and Ci- gheteroaryl are optionally substituted with one, two, or three R 20d ;
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0)
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, -CH 2 -C3- 6cycloalkyl, C 2 -9heterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -C I - gheteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2 -9heterocycloalkyl, -CH 2 -C 2 -9heterocycloalkyl
- Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 20f ; each R 20a , R 20b , R 20c , R 20d , R 20e , R 20f , R 20g , and R 201 are each independently selected from halogen, -CN, Ci- 6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, -CH 2 -C3-6cycloalkyl, C 2 -9heterocycloalkyl, -CH 2 -C 2.
- each R 22 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2.
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 16 ) or N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- Ci-Cealkyl C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or 2 to 4 membered heteroalkylene linker, wherein Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and 2 to 4 membered heteroalkylene linker are optionally substituted with one, two, or three R 20a ;
- R 7 is a 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl, wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a C3-i 2 cycloalkyl, Ci-nheterocycl
- Ci-nheterocycloalkyl, C 6 -i 2 aryl, or Ci-nheteroaryl are optionally substituted with one, two, or three R 20a ; each R 1 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci- 6 haloalkyl, C3- i 2 cycloalkyl.
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, Ci-Cealkyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. dictcrocycloalkyl. C 6 -ioaryl, Ci-yhctcroan l.
- R 17 is -lA-R 19 ;
- L 1 is selected from a bond, Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ),
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), - C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , - S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12
- gheterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201 ; or R lf and R lg are joined to form a 4-7 membered heterocycloalkyl ring or a 4-7 membered cycloalkyl ring, wherein the 4-7 membered heterocycloalkyl ring or 4-7 membered cycloalkyl ring are optionally substituted with one, two, or three R 201 ;
- R lc is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, CV,- ioaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 201
- R 19 is selected from a C3-i 2 cycloalkyl, C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl, wherein the C3- i 2 cycloalkyl, C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3- 6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -
- R 12a is selected from Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -C(R 12c ) 2 -C3-iocycloalkyl, C 2.
- Ci-9heterocycloalkyl gheterocycloalkyl, -C(R 12c ) 2 -C 2 -9heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci-9heteroaryl, and Ci-9heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -C(R 12c ) 2 -C3-iocycloalkyl, C 2 -9heterocycloalkyl, -C(R 12c ) 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci-9heter
- R 12b is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -C(R 12c ) 2 -C3-iocycloalkyl, C 2.
- Ci-9heterocycloalkyl gheterocycloalkyl, -C(R 12c ) 2 -C 2 -9heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci-9heteroaryl, and Ci-9heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -C(R 12c ) 2 -C3-iocycloalkyl, C 2 -9heterocycloalkyl, -C(R 12c ) 2 -C 2 -9heterocycloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci-9heter
- R 12c is independently selected from hydrogen and R 20k ;
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0)
- Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are optionally substituted with one, two, or three R 20f ; each R 20a , R 20b , R 20c , R 20d , R 20e , R 20f , R 20g , R 201 , and R 20k are each independently selected from halogen, oxo, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2 - gheterocycloalkyl, C 6 -ioaryl, -CFF-
- R 7 is a 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl, wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the a 4- 12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 17 ) and J is C(R 16 ), or V is C(R 17 ) and J is N, or J is C(R 17 ) and V is C(R 16 ), or J is C(R 17 ) and V is N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- Ci-Cealkyl C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or 2 to 4 membered heteroalkylene linker, wherein Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and 2 to 4 membered heteroalkylene linker are unsubstituted or optionally substituted;
- R 7 is a 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl, wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl are unsubstituted or optionally substituted;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. dictcrocycloalkyl. C 6 -ioaryl, Ci-dictcroarvl.
- R 17 is -G-R 19 ;
- L 1 is selected from a bond, G-Galkyl, C 2 -C 6 alkenyl, C 2 -Galkynyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), - C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , - S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12
- gheterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are unsubstituted or optionally substituted; or R lf and R lg are joined to form a 4-7 membered heterocycloalkyl ring or a 4-7 membered cycloalkyl ring, wherein the 4- 7 membered heterocycloalkyl ring or 4-7 membered cycloalkyl ring are unsubstituted or optionally substituted;
- R lc is selected from hydrogen, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, G,. loaryl, and Ci- ⁇ j hctcroaiyl. wherein Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, C6-ioaryl, and Ci-gheteroaryl are unsubstituted or optionally substituted;
- R 19 is selected from a C 3 -i 2 cycloalkyl, C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl, wherein the G- ncycloalkyl, C 2 -iiheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl are unsubstituted or optionally substituted;
- R 16 is selected from hydrogen, halogen, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, G- gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S
- R 12a is selected from Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -G-iocycloalkyl, G- gheterocycloalkyl, -C(R 12c ) 2 -G- 9 heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -G-ioaryl, -C(R 12c ) 2 -G- 9 heteroaryl, and Ci- 9 heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocycloalkyl, C 6 -
- R 12b is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci- 9 heteroaryl, and Ci- 9 heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 hetero
- R 12c is selected from hydrogen, halogen, oxo, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C6-ioaryl, -CH 2 -C6-ioaryl, -CH 2 -C 1.
- Ci-sheteroaiyl Ci-sheteroaiyl, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(0)0R 22 , -C(0)N(R 22 )(R 23 ), - C(0)C(0)N(R 22 )(R 23 ), -0C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)0R 25 , -N(R 24 )C(0)R 25 , - N(R 24 )S(0) 2 R 25 , -C(0)R 25 , -S(0) 2 R 25 , -S(0) 2 N(R 22 )(R 23 ), -0CH 2 C(0)0R 22 , and -0C(0)R 25 , wherein Ci- 6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycl
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci-dictcroarvl.
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -C 1 - gheteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl,
- R 7 is a 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl, wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the a 4- 12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted or unsubstituted.
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 16 ) or N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- Ci-Cealkyl C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or 2 to 4 membered heteroalkylene linker, wherein Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and 2 to 4 membered heteroalkylene linker are unsubstituted or optionally substituted;
- R 7 is a 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl, wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 6-12 membered aryl, or 5-12 membered heteroaryl are unsubstituted or optionally substituted;
- R 8 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2. dictcrocycloalkyl. C 6 -ioaryl, Ci-dictcroarvl.
- R 17 is -G-R 19 ;
- L 1 is selected from a bond, G-Galkyl, C 2 -C 6 alkenyl, C 2 -Galkynyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-6cycloalkyl, C 2 -9heterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), - C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , - S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12
- gheterocycloalkyl, C 6 -ioaryl, and Ci-gheteroaryl are unsubstituted or optionally substituted; or R lf and R lg are joined to form a 4-7 membered heterocycloalkyl ring or a 4-7 membered cycloalkyl ring, wherein the 4- 7 membered heterocycloalkyl ring or 4-7 membered cycloalkyl ring are unsubstituted or optionally substituted;
- R lc is selected from hydrogen, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, G,. loaryl, and Ci- ⁇ j hctcroaiyl. wherein Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, C6-ioaryl, and Ci-gheteroaryl are unsubstituted or optionally substituted;
- R 19 is selected from a C 3 -i 2 cycloalkyl, C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl, wherein the G- ncycloalkyl, C 2 -iiheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl are unsubstituted or optionally substituted;
- R 16 is selected from hydrogen, halogen, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, G- gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S
- R 12a is selected from Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -G-iocycloalkyl, G- gheterocycloalkyl, -C(R 12c ) 2 -G- 9 heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -G-ioaryl, -C(R 12c ) 2 -G- 9 heteroaryl, and Ci- 9 heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocycloalkyl, C 6 -
- R 12b is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci- 9 heteroaryl, and Ci- 9 heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 hetero
- R 12c is selected from hydrogen, halogen, oxo, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C6-ioaryl, -CH 2 -C6-ioaryl, -CH 2 -C 1.
- Ci-sheteroaiyl Ci-sheteroaiyl, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(0)0R 22 , -C(0)N(R 22 )(R 23 ), - C(0)C(0)N(R 22 )(R 23 ), -0C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)N(R 22 )(R 23 ), -N(R 24 )C(0)0R 25 , -N(R 24 )C(0)R 25 , - N(R 24 )S(0) 2 R 25 , -C(0)R 25 , -S(0) 2 R 25 , -S(0) 2 N(R 22 )(R 23 ), -0CH 2 C(0)0R 22 , and -0C(0)R 25 , wherein Ci- 6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycl
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 2 - gheterocycloalkyl, C 6 -ioaryl, Ci-gheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 ,
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl, -CH 2 -C 6 -ioaryl, -CH 2 -C 1 - gheteroaryl, and Ci-gheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, -CH 2 -C 3 - 6cycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -ioaryl,
- R 7 is a 4- 12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl, wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the a 4- 12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted or unsubstituted.
- V is C(R 17 ) and J is C(R 16 ), or V is C(R 17 ) and J is N, or J is C(R 17 ) and V is C(R 16 ), or J is C(R 17 ) and V is N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- Ci-Cealkyl C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or 2 to 4 membered heteroalkylene linker, wherein Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and 2 to 4 membered heteroalkylene linker are optionally substituted with one, two, or three R 20a ;
- R 7 is a 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl, wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; wherein two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a 3-12 membered cycloalkyl, 3-12 membered
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, G-Galkyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, C 2 -9heterocycloalkyl, G- i 2 aryl, Ci-nheteroaiyl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), - C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S
- R 17 is -L ! -R 19 ;
- L 1 is selected from a bond, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ), and C
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, C6-i2aryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), - C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , - S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12
- R lc is selected from hydrogen, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, naryl, Ci-nheteroaryl, wherein C h alky 1, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, CV,. naryl, and Ci-nheteroaryl are optionally substituted with one, two, or three R 201 ;
- R 19 is selected from a C3-i2cycloalkyl, C2-nheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl, wherein the C3- ncycloalkyl, C2-iiheterocycloalkyl, C6-i2aryl, and C2-i2heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, oxo, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3- locycloalkyl, C2-9heterocycloalkyl, Gs-naryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , - 0C(0)N(R 12
- R 16 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2- gheterocycloalkyl, C6-i2aryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -
- R 12a is selected from Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocyeloalkyl, C6-ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci- 9 heteroaryl, and Ci-gheteroaryl, wherein Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocycloal
- R 12b is selected from hydrogen, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocyeloalkyl, C6-ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci- 9 heteroaryl, and Ci-gheteroaryl, wherein Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocycl
- R 12c is independently selected from hydrogen and R 20k ;
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, C 6 -i 2 aryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15
- each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -CH 2 -C 3 - locycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -i 2 aryl, -CH 2 -C 6 -i 2 aryl, -CH 2 -C 1 - nheteroaryl, and Ci-nheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -CH 2 -C 3 - locycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C
- each R 22 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, C 2. dictcrocycloalkyl.
- C 6 -i 2 aryl, and Ci-nheteroaryl each R 23 is independently selected from H and Ci- 6 alkyl; each R 24 is independently selected from H and Ci- 6 alkyl; each R 25 is independently selected from Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, C 2. siheterocycloalkyl, C 6 -i 2 aryl, and Ci-nheteroaryl; and indicates a single or double bond such that all valences are satisfied.
- W is C(O), S(O), or S(0) 2 ;
- V is C(R 16 ) or N;
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(O)-, -S(0) 2 N(R 14 )-, -
- Ci-Cealkyl C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or 2 to 4 membered heteroalkylene linker, wherein Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and 2 to 4 membered heteroalkylene linker are optionally substituted with one, two, or three R 20a ;
- R 7 is a 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl, wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, and 5-12 membered heteroaryl each comprises one or more ring nitrogen atoms or one or more ring oxygen atoms and wherein the 4-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 7-12 membered aryl, or 5-12 membered heteroaryl are optionally substituted with one or more R 1 , optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; two substituents selected from R 1 , R 4 , and R 6 that are bonded to the same or adjacent atoms are optionally joined to form a 3-12 membered cycloalkyl, 3-12 membered heterocycl
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond, Ci-Cealkyl, -0-, -N(R 14 )-, -C(O)-, -N(R 14 )C(0)-, -C(0)N(R 14 )-, - S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, -OCON(R 14 )-, - N(R 14 )C(0)0-, and -N(R 14 )C(0)N(R 14 )-; each R 5 is independently hydrogen, or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein;
- R 8 is selected from halogen, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, i 2 aryl, Ci-nheteroaiyl, -OR 12 , -SR 12 , -N(H)(R 12 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), - C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15 , -S(0) 2 R
- R 17 is -lA-R 19 ;
- L 1 is selected from a bond, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, -0-, -N(R 14 )-, -C(0)-, -N(R 14 )C(0)-, - C(0)N(R 14 )-, -S-, -S(0) 2 -, -S(0)-, -S(0) 2 N(R 14 )-, -S(0)N(R 14 )-, -N(R 14 )S(0)-, -N(R 14 )S(0) 2 -, - OCON(R 14 )-, -N(R 14 )C(0)0-, N(R le ), C(0)N(R lc ), S(0) 2 N(R lc ), S(0)N(R lc ), C(R lf )(R lg )0, C(R lf )(R lg )N(R lc ), and C(R
- R le , R lf , and R lg are independently selected from hydrogen, halogen, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, Gs-naryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), - C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , - S(0)R 15 , -0C(0)R 15 , -C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12
- R 19 is selected from a C 3 -i 2 cycloalkyl, C 2 -nheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl, wherein the C 3 - ncycloalkyl, C 2 -iiheterocycloalkyl, C 6 -i 2 aryl, and C 2 -i 2 heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, oxo, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 - locycloalkyl, C 2-9 heterocycloalkyl, C 6 -i 2 aryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12
- R 16 is selected from hydrogen, halogen, -CN, Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, C 6 -i 2 aryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R 15
- R 12a is selected from Ci-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci- 9 heteroaryl, and Ci- 9 heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocycloal
- R 12b is selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, -C(R 12c ) 2 -C 2-9 heterocyeloalkyl, C 6 -ioaryl, -C(R 12c ) 2 -C 6 -ioaryl, -C(R 12c ) 2 -Ci- 9 heteroaryl, and Ci- 9 heteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -C(R 12c ) 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -C(R 12c ) 2 -C 2-9 hetero
- R 12c is independently selected from hydrogen and R 20k ;
- X is C(R 3 ) or N
- R 3 is selected from hydrogen, halogen, -CN, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, C 2 - gheterocycloalkyl, C 6 -i 2 aryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), - N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14 )S(0) 2 R 15 , -C(0)R 15 , -S(0)R 15 , -0C(0)R 15 , - C(0)N(R 12 )(R 13 ), -C(0)C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)R
- gheterocycloalkyl, C 6 -i 2 aryl, and Ci-nheteroaryl are optionally substituted with one, two, or three R 20f ; each R 20a , R 20b , R 20c , R 20d , R 20e , R 20f , R 20g , R 201 , and R 20k is independently selected from halogen, oxo, -CN, G- 6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C3-iocycloalkyl, -CH 2 -C3-iocycloalkyl, C 2 -9heterocycloalkyl, -CH 2 -C 2.
- one R 4 is an electrophilic moiety capable of forming a covalent bond with a cysteine, serine, or aspartate residue at an amino acid position corresponding to 12 or 13 of a human KRAS protein;
- one R 4 is an electrophilic moiety capable of forming a covalent bond with a cysteine, serine, or aspartate residue at an amino acid position corresponding to 12 or 13 of a human KRAS protein;
- W is C(O); V is C(R 17 ) and J is C(R 16 );
- R 10 is -L 7 -R 7 ;
- L 7 is a bond, -0-, or -N(R 14 )-;
- R 7 is a 3-12 membered heterocycloalkyl, wherein the 3-12 membered heterocycloalkyl comprises one or more ring nitrogen atoms and wherein the 3-12 membered heterocycloalkyl, is optionally substituted with one or more R 4 , and optionally substituted with one or more R 6 ; each R 4 is independently selected from halogen, oxo, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C 2 -9heterocycloalkyl, C 6 -i2aiyl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R
- naryl, and Ci-nheteroaryl are optionally substituted with one, two, or three R 20a ;
- one R 4 is optionally independently an electrophilic moiety capable of forming a covalent bond with a cysteine, serine, or aspartate residue at an amino acid position corresponding to 12 or 13 of a human KRAS protein;
- R 6 is -L 2 -R 5 ; each L 2 is independently selected from a bond and -C(O)-; each R 5 is independently hydrogen or a group other than an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS protein; each R 5 is independently selected from hydrogen, halogen, oxo, -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3- locycloalkyl, C2-9heterocycloalkyl, Gs-naryl, Ci-nheteroaryl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , - 0C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)N(R 12 )(R 13 ), -N(R 14 )C(0)0R 15 , -N(R 14
- R 8 is selected from -CN, Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, C2-9heterocycloalkyl, and -C(0)R 12 , wherein Ci- 6 alkyl, C2-6alkenyl, C2-6alkynyl, C3-iocycloalkyl, and C2-9heterocycloalkyl are optionally substituted with one, two, or three R 20c ;
- R 17 is -LCR 19 ;
- L 1 is a bond;
- R 19 is selected from a C 6 -i 2 aryl and C 2 -i 2 heteroaryl, wherein the C 6 -i 2 aryl and C 2 -i 2 heteroaryl are optionally substituted with one, two, three, four, five, six, or seven R 11 ; each R 11 is independently selected from halogen, oxo, -CN, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 - 6 cycloalkyl, Cz-sheterocycloalkyl, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(0)0R 12 , -C(0)R 12 , -C(0)N(R 12 )(R 13 ), and -N(R 14 )C(0)R 12 , wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6
- R 16 is selected from hydrogen and halogen
- R 2 is -0-R 12a ;
- R 12a is -C(R 12c ) 2 -C 2-9 heterocycloalkyl, wherein -C(R 12c ) 2 -C 2-9 heterocyeloalkyl is optionally substituted with one, two, or three R 20d ;
- R 12c is independently selected from hydrogen and Ci- 3 alkyl
- X is C(R 3 ) orN
- R 3 is selected from hydrogen and -CN; each R 12 is independently selected from hydrogen, Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -CH 2 -C 3 - locycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -i 2 aryl, -CH 2 -C 6 -i 2 aryl, -CH 2 -C 1 - nheteroaryl, and Ci-nheteroaryl, wherein Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -CH 2 -C 3 - locycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2-9 heterocycloalkyl, C 6 -i 2 aryl, -CH 2 -C 6 -
- each R 20a , R 20c , R 20d , R 20e , R 20f , and R 201 is independently selected from halogen, oxo, -CN, Ci- 6 alkyl, C 2 - 6alkenyl, C 2-6 alkynyl, C 3 -iocycloalkyl, -CH 2 -C 3 -iocycloalkyl, C 2-9 heterocycloalkyl, -CH 2 -C 2 - gheterocycloalkyl, C 6 -i 2 aryl, -CH 2 -C 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente divulgation concerne des composés, certains de leurs sels pharmaceutiquement acceptables et leurs méthodes d'utilisation. Les composés et les méthodes offrent un éventail d'utilités en tant qu'outils de thérapeutique, de diagnostic et de recherche. En particulier, ces compositions et méthodes sont utiles pour réduire la production de signalisation de protéines oncogènes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163210474P | 2021-06-14 | 2021-06-14 | |
US202163291320P | 2021-12-17 | 2021-12-17 | |
US202263313132P | 2022-02-23 | 2022-02-23 | |
PCT/US2022/033305 WO2022266015A1 (fr) | 2021-06-14 | 2022-06-13 | Composés hétéroaryle fusionnés utiles en tant qu'agents anticancéreux |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4355751A1 true EP4355751A1 (fr) | 2024-04-24 |
Family
ID=82483189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22740705.3A Pending EP4355751A1 (fr) | 2021-06-14 | 2022-06-13 | Composés hétéroaryle fusionnés utiles en tant qu'agents anticancéreux |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4355751A1 (fr) |
JP (1) | JP2024521473A (fr) |
AU (1) | AU2022293663A1 (fr) |
CA (1) | CA3221608A1 (fr) |
WO (1) | WO2022266015A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023196086A2 (fr) * | 2022-04-08 | 2023-10-12 | Mirati Therapeutics, Inc. | Polythérapies comprenant un inhibiteur de sos1 et un inhibiteur d'egfr |
WO2023196218A2 (fr) * | 2022-04-08 | 2023-10-12 | Mirati Therapeutics, Inc. | Polythérapies comprenant un inhibiteur de sos1 et un inhibiteur de mek |
WO2023215906A1 (fr) * | 2022-05-06 | 2023-11-09 | Hangzhou Jijing Pharmaceuticaltechnology Limited | Chimères ciblant la protéolyse kras g12d |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
WO2024031088A1 (fr) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
WO2024152247A1 (fr) * | 2023-01-18 | 2024-07-25 | Nikang Therapeutics , Inc. | Composés bifonctionnels pour la dégradation de kras g12d par l'intermédiaire de la voie ubiquitine-protéasome |
WO2024112654A1 (fr) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Inhibiteurs de kras spirocycliques de dihydropyranopyrimidine |
WO2024206858A1 (fr) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions pour induire une hydrolyse de ras gtp et leurs utilisations |
WO2024211712A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
WO2024211663A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016119707A1 (fr) * | 2015-01-29 | 2016-08-04 | Hutchison Medipharma Limited | Nouveaux composés hétéroaryliques et hétérocycliques, compositions et procédés |
EP3908283A4 (fr) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
CN112552294B (zh) * | 2019-09-10 | 2023-12-19 | 上海翰森生物医药科技有限公司 | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 |
CN115968286A (zh) * | 2020-08-26 | 2023-04-14 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物,其制备方法和用途 |
-
2022
- 2022-06-13 CA CA3221608A patent/CA3221608A1/fr active Pending
- 2022-06-13 WO PCT/US2022/033305 patent/WO2022266015A1/fr active Application Filing
- 2022-06-13 EP EP22740705.3A patent/EP4355751A1/fr active Pending
- 2022-06-13 JP JP2023577155A patent/JP2024521473A/ja active Pending
- 2022-06-13 AU AU2022293663A patent/AU2022293663A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022293663A1 (en) | 2023-12-21 |
JP2024521473A (ja) | 2024-05-31 |
CA3221608A1 (fr) | 2022-12-22 |
WO2022266015A1 (fr) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022293663A1 (en) | Fused heteroaryl compounds useful as anticancer agents | |
AU2022220678A1 (en) | Heterocyclic compounds and uses thereof | |
US11648254B2 (en) | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | |
WO2022047260A1 (fr) | Composés hétérocycliques et leurs utilisations | |
WO2022081912A2 (fr) | Hétérocycles et leurs utilisations | |
WO2023141300A1 (fr) | Composés hétérocycliques et leurs utilisations | |
AU2017281903A1 (en) | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | |
US12059425B2 (en) | Heterocyclic compounds and uses thereof | |
AU2022221145A1 (en) | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | |
WO2020027083A1 (fr) | Composition pharmaceutique comprenant un composé quinazoline en tant que principe actif | |
US20240109918A1 (en) | Heterocyclic compounds and uses thereof | |
US20240116951A1 (en) | Heterocyclic compounds and uses thereof | |
TW202340209A (zh) | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 | |
JP6586463B2 (ja) | PI3Kβ阻害剤としての複素環連結イミダゾピリダジン誘導体 | |
WO2022271562A1 (fr) | Hétérocycles et leurs utilisations | |
CN117120058A (zh) | 杂环化合物及其用途 | |
US11912708B2 (en) | Macrocyclic heterocycles and uses thereof | |
AU2023264608A1 (en) | Heterocyclic compounds and uses thereof | |
EP4389751A1 (fr) | Composés hétérocycliques et leurs utilisations | |
US20240368191A1 (en) | Heterocyclic compounds and uses thereof | |
WO2023205701A1 (fr) | Hétérocycles macrocycliques et leurs utilisations | |
TW202438056A (zh) | 雜環化合物及其用途 | |
CN117794940A (zh) | 用作抗癌药剂的稠合杂芳基化合物 | |
US20240270736A1 (en) | Macrocyclic heterocycles and uses thereof | |
WO2024138052A1 (fr) | Hétérocycles et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20231213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |